Make a Compelling Connection ONSITE GUIDE · 2017. 8. 25. · big pharma BIOTECH family offices MEDTECH angels fundraising boot camp ... focused on Precision Medicine and will be

Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an

opportunity to Make a Compelling Connection

ONSITE GUIDE

#RESIBOS2015 | RESIConference.com | September 16, 2015 | The Westin Copley Place

Connecting Products, Services & Capital

LIFE SCIENCENATION

SEPTEMBER 16, 2015

BOSTON, MARESI

Essex Ballroom

Elevators

Restroom

RefreshmentStation

Staffordshire

REGISTRATION

Track 2

investor

panelsSt. George A

St. George B

workshops

St. George C&D

Track 3

Track 1

investor

panels

Reception

Buffet Table

PARTNERING Forum

EXHIBITHALL

Breakfast Buffet & Lunch

exhibiting companies

resi innovation challenge

Buffet/Cocktail

Cocktail

12 3

4 5 6 7 8

914

1

15

10 11 12 13

21

27 28 29 30

6 7 8 9 10

11 12 13 14 15

16 17 18 19 2016 17 18 19

22 23 24 25 2620 21 22 23

24 25 26 27

2 3 4 5

Welcome from Dennis Ford - - - - - - - 2

RESI Schedule - - - - - - - - - - - - - - - - - 3

Investor Panels - - - - - - - - - - - - - - - 19

Early Stage Workshops - - - - - - - - - 38

RESI Innovation Challenge - - - - - - - 5

Partnering Forum - - - - - - - - - - - - - - 41

Exhibiting Companies - - - - - - - - - - 13

Media Partners - - - - - - - - - - - - - - - 44

Sponsors - - - - - - - - - - - - - - - - - - - - 42

1

content

General Information - - - - - - - - - - - 45

Notes - - - - - - - - - - - - - - - - - - - - - - 48

content

Sincerely,

Dennis FordFounder & CEO, Life Science Nation

2

welcome from dennis ford

RESI’s expanded presence has served to power up the central focus of the event – the RESI Partnering Forum. With more investors and more entrepreneurs in the mix, we’ve only increased your odds of making a compelling connection at RESI. By using the RESI Partnering system to �nd fellow attendees based on �t, you can �nd meeting partners who align with your focus. That’s the factor that makes RESI a productive place to meet and begin new dialogues. We’d like to extend a special welcome to the speakers featured on the two tracks of RESI Investor Panels that are taking place throughout the day, and also to the RESI Workshops presenters who have come to share their insights and tactical knowhow with RESI’s audience today. We’d also like to bring your attention to the RESI Innovation Challenge. The RESI Innovators are showcasing cutting-edge life science technologies in poster displays throughout the exhibit hall. Inside your RESI badge you’ll �nd �ve tokens of RESI Cash you can use to “invest” in the most promising of these technologies. Take the time to invest your RESI Cash wisely, and join us at the evening reception as we announce the winners! Thank you for being here today. We trust that you will make compelling connections at RESI Boston, and we hope to see you again in San Francisco on January 12th, 2016.

Two years ago on September 16th, 2013, LSN hosted the very �rst Rede�ning Early Stage Investments (RESI) Conference right here in Boston. Two years later, after highly successful events at new venues in San Francisco and Houston, we return to Boston for the sixth RESI Conference. Welcome! RESI has come full circle back to the city where the event began.


LIFE SCIENCENATION

resi schedule

3

5:00 - 7:00 PM: Cocktail Reception (Crystal Ballroom & Crystal Lounge)

7:00 - 8:00 AM: Registration & Breakfast

8:00-

8:50AM

9:00-

9:50AM

10:00-

10:50AM

11:00-

11:50AM

BIOTECHAngels

Preclinical & phase Iinvestors

MORNINGEARLY STAGEPARTNERING

FORUM

bigpharma

BIOTECHfamily offices

MEDTECHangels

fundraisingboot camp

boston innovation capital

Medical DEVICEINVESTORS

medtechstrategics

12:00 - 1:00 PM: Break for Lunch

5:00 - 7:00 PM: Cocktail Reception

1:00-

1:50PM

2:00-

2:50PM

3:00-

3:50PM

4:00-

4:50PM

PHASE II & PHASE IIIINVESTORS

CorporateVenture capital

funding & RESOURCESFOR STARTUPS

AFTERNOONEARLY STAGEPARTNERING

FORUM

venturephilanthropy

tales fromthe road

branding &messaging

Diagnosticinvestors

healthcare itinvestors

Globalinvestors

Track 1:Investor Panels

Investor Panels

Early StageEntrepreneurWorkshops

PartneringForum

Track 2: Track 3: Track 4:

RESEARCHINGGLOBAL INVESTORS

medtechfamily offices

Sponsored by:Sponsored by: Sponsored by:Sponsored by:

Connecting Products, Services & CapitalLIFE SCIENCE NATION


Due to the popularity of

Sessions, there is no workshop scheduled to run

during this time slot.

How to ValueYour Startup

Non-Dilutive Funding

Government Grants & Contracts

A New Capital Raising AlternativeReg A+


BOSTON, MASEPTEMBER 26, 2016

TORONTO, CANADAjune 23, 2016

Houston, txapril 4, 2016

SAN FRANCISCO, CAJANUARY 12, 2016

2016The RESI Conference Series offers fundraising CEOs an opportunity to meet early stage investors that are a �t for their sector four times every year.

Use the discount code LSNRESI2016 for $100 off of your RESI 2016 registration.

We welcome you to participate in the RESI Innovation Challenge!


LSN Investor Platform for a year.

The RESI Innovation Challenge is a virtual investment contest, and the investor is you!As you explore the exhibit hall, you will encounter 30 RESI Innovators showcasing their technology via poster displays. Along with your RESI attendee badge, you will �nd �ve RESI Cash tokens that you can use to 'invest' in the most promising RESI Innovators. Take a look around this collection of cutting-edge life science technology, and leave your RESI Cash with the entrepreneurs that most inspire you. The invested capital will be tallied up and the top three winners will be awarded during the cocktail reception at the end of the day. Winners will be featured in the Life Science Nation (LSN) newsletter with readership of 20,000.

• First prize winner of the RESI Innovation Challenge will receive complimentary subscription to the LSN Investor Platform for a year.

• Second prize winner will receive two complimentary RESI tickets, to be used within 12 months. • Third prize winner will receive one complimentary RESI ticket, to be used within 12 months.

5

$100,000

RESI Innovation Challenge RESI CASH

www.RESIConference.com

6


RESI Innovators

Easel 1 Easel 2 Easel 4Easel 3

Easel 16Easel 13 Easel 14 Easel 15

Easel 30Easel 29

Easel 27Easel 25 Easel 26 Easel 28

Easel 6 Easel 8Easel 7Easel 5

Easel 9 Easel 12Easel 10 Easel 11

Easel 22Easel 21 Easel 24Easel 23

Easel 18 Easel 19Easel 17 Easel 20

The RESI Innovation Challenge is a virtual investment contest, and the investor is you!As you explore the exhibit hall, you will encounter 30 RESI Innovators showcasing their technology via poster displays. Along with your RESI attendee badge, you will �nd �ve RESI Cash tokens that you can use to 'invest' in the most promising RESI Innovators. Take a look around this collection of cutting-edge life science technology, and leave your RESI Cash with the entrepreneurs that most inspire you. The invested capital will be tallied up and the top three winners will be awarded during the cocktail reception at the end of the day. Winners will be featured in the Life Science Nation (LSN) newsletter with readership of 20,000.

• First prize winner of the RESI Innovation Challenge will receive complimentary subscription to the LSN Investor Platform for a year.

• Second prize winner will receive two complimentary RESI tickets, to be used within 12 months. • Third prize winner will receive one complimentary RESI ticket, to be used within 12 months.

Rna Diagnostics is commercializing the RNA Disruption Assay (RDA™) to address the serious problem of over-treatment of cancers with ineffective chemotherapy. RDA accurately assesses effectiveness of chemotherapy in real-time. Chemotherapy effect is assessed as early as 14 days after therapy initiation by quantifying tumour RNA disruption. High RNA disruption is strongly correlated with pathological complete response and enhanced long term disease free survival. RDA assesses treatment ef�cacy of conventional and targeted cancer drugs in breast cancer. RDA is delivered as a lab developed test service. No FDA approval required. Collaborations and prospective trials of RDA in multiple cancers are underway / planned in North America, Europe & Asia. RDA provides patients with improved outcomes while reducing cost for healthcare payers.

SolaranRx, Inc. is an emerging growth company developing a new class of therapies and companion imaging agents for the treatment of metastatic melanoma. SolaranRx precisely targets deadly melanoma tumors with a radiolabeled peptide, offering unique therapeutic potential with minimal side effects. Our novel peptide technology shows highly speci�c binding to melanoma enabling physicians to identify patients for treatment, deliver targeted radiation to melanoma tumors and visualize patient response. SolaranRx is focused on developing its lead product (SRX-1177), which has led to Orphan Drug designation by the FDA based on compelling pre-clinical evidence. SolaranRx is strongly differentiated in the projected $5.6 billion global melanoma drug market by offering a distinctive mechanism of action that avoids the shortcomings of current therapies.

Gamma Medica, Inc. is a women’s health company focused on overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. The company’s LumaGEM® MBI system is the �rst commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90% sensitivity and speci�city, LumaGEM MBI has been shown to signi�cantly improve cancer detection in women with dense breast tissue by 400% with fewer false positives relative to anatomical imaging technologies. For more information visit www.gammamedica.com

Aldatu Biosciences is a Boston-based, seed-funded biotechnology company developing innovative diagnostic tools based on its proprietary genotyping platform, PANDAA. Aldatu is committed to commercializing products that address diagnostic challenges in global health, primarily in HIV and other infectious diseases, and that improve both the quality of patient care and healthcare cost-ef�ciency.

SynVivo is commercial stage company that introduced its leading edge tools for drug discovery and research. Combining the two high-tech domains of micro�uidics and bioengineering, SynVivo chips allow scientists to visualize, manipulate and analyze how drugs behave in real time offering a true breakthrough in drug development tools. The company is now focused on Precision Medicine and will be at the forefront as it demonstrates its technology’s ability to show, in real time, how a patient will respond to different drug/drug combination therapies. With cancer as the �rst application, a physician can see if the therapy is working (for example, slowing tumor growth), verify drug kinetics and dynamics and, if the tumor morphs, take remedial action, all without compromising care for the patient. Once a therapy is determined to be effective on the SynVivo cancer chip, it can be administered to the patient with predictable outcomes.

Metal coordination, or attaching a metal to an active agent to control its absorption and release, represents a signi�cant advance in drug delivery and development. It is a powerful, �exible and elegant means to create a new generation of safer and more effective patent protected drugs (“MCPs”). In addition to imparting a range of desired characteristics, metal coordination enjoys signi�cant regulatory advantages. MCPs of approved drugs are eligible for approval under section 505(b)(2), which allows for faster and less expensive drug development. Moreover, they are patentable as new compositions of matter even if the parent molecule is well known. Synthonics intends to begin human trials in 2016 on its controlled release formulations of levodopa for Parkinson’s disease and liothyronine (T3) for hypothyroidism.

7

resi innovatorsEasel 1 - 8

JLABS, part of Johnson & Johnson Innovation, LLC, is a network of open innovation research centers providing emerging companies with many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an

option to quickly expand when they have the resources to do so.

JLABS

make the CONNECTION

FIND OUT MORE ABOUT HOW YOU CAN JOIN US AT

JLABS.jnjinnovation.com

WE WANT YOU!

employees globallyworldwide

sq. ft. of lab and

WuXi’s Dream

8.5” wide x 5.5” high.indd 1 2015/8/20 9:46:54

CellSight is a clinical stage PET imaging tools company that can increase probability of clinical success of immunotherapies by determining early if the immunotherapy is working in a cancer patient. Cancer immunotherapies that harness the body’s immune system to help �ght cancer do not work for everyone; in fact, success rates can be as low as 20%! Many patients seem to get worse before symptoms ease and clinical bene�t can be observed. CellSight’s PET tracers provide clinicians with imaging tools to assess immunotherapy response early in the treatment cycle to make informed decisions. Our lead PET tracer is targeted at imaging activated T cells which is critical in any immune modulated response. Clinical trials are currently in progress at UCSF.

KIYATEC prioritizes accurate ex vivo prediction of patients' drug response, focused primarily on data correlation to human clinical outcomes. Our drug response pro�ling services utilize phenotypic 3D cell-based models for predicting patient response. KIYATEC’s 3D perfusion tissue microenvironments are particularly useful for investigating ef�cacy and modeling resistance of cancer therapeutics.

Symbiotix Biotherapies was founded on the basis of fundamental new advances in understanding the microbiome. Building on over a decade of research at Harvard, Caltech and Dartmouth by pre-eminent thought leaders in the �eld, Symbiotix is developing novel molecular therapeutics derived from the human microbiome. Our Company’s programs target immune-mediated indications such as multiple sclerosis, in�ammatory bowel disease and other diseases with wide prevalence, long-term treatment requirements and huge unmet medical needs. Our lead clinical candidate is a �rst-in-class agent targeting Tregs and is rapidly advancing into human clinical trials. We have a dominant IP position including composition-of-matter �lings, and are developing an entirely new class of microbiome-derived molecules for major indications.

8




JLABS

make the CONNECTION



WE WANT YOU!


sq. ft. of lab and

WuXi’s Dream

8.5” wide x 5.5” high.indd 1 2015/8/20 9:46:54

PHD Biosciences is developing a small molecule inhibitor (Ki = 86 pM) of methylthioadenosine phosphorylase (MTAP) for the treatment of triple negative breast cancer (TNBC). Inhibition of MTAP results in increased methylthioadenosine levels and anticancer effects via the modulation of epigenetic regulation in cancer cells. In preclinical studies, MTDIA has displayed potent ef�cacy and an excellent safety pro�le. MTDIA is currently poised GLP toxicity studies and CMC scale up prior. It is anticipated that MTDIA will be IND ready in 9-12 months from Sept 2015. PHD is currently seeking investment or a partner to facilitate the initiation of a Phase I clinic trial.

AblaCor Medical Corporation is dedicated to the development and commercialization of the CircumBlator™ AF Ablation Catheter System, a new product that will revolutionize the treatment of atrial �brillation (AF), the most common irregular heart rhythm and a serious debilitating disorder. The CircumBlator, with its novel anchor design for enhanced lesion creation, offers a procedure with a low complication rate, freedom from AF, and few repeat procedures. Supported by a prominent scienti�c advisory board, the company has a proven team of business and technical professionals with expertise in electrophysiology and cardiology. AblaCor has one issued patent and �led six US and four OUS utility applications. AblaCor seeks $1.5M to complete in vivo testing and $11M total to achieve CE Mark.

CytoSorbents Corporation (NASDAQ: CTSO) is a critical care immunotherapy company working to control deadly in�ammation in life-threatening diseases in the ICU, such as sepsis and infection, trauma, burn injury, pancreatitis, lung injury, and liver failure, or in�ammation caused by complications of cardiac and other types of surgery. Left unchecked, this body-wide in�ammation can rapidly lead to organ failure, the leading cause of death in the ICU for which no therapy has been effective. The company’s �agship product is CytoSorb®, an extracorporeal cytokine adsorber that reduces the “fuel to the �re” of in�ammation by lowering a broad range of in�ammatory mediators such as toxins and cytokines in the blood. The CytoSorb® cartridge works with standard hemodialysis machines in a hospital to rapidly purify a patient’s blood and has been used safely in more than 6,000 human treatments. CytoSorb® is approved in the European Union and is distributed in more than 30 countries worldwide.

Actinobac Biomed, Inc. is engaged in the development and commercialization of biopharmaceuticals with multiple potential indications. The company’s product portfolio is based upon Leukothera®, a bacterial protein usually found in the human mouth that binds to and depletes a speci�c subset of white blood cells (WBCs) involved in the mechanism of a variety of illnesses including hematological malignancies, autoimmune/in�ammatory diseases, and HIV infection. Leukothera® rapidly targets and kills only WBCs expressing LFA-1, which is abundantly expressed on disease related WBCs. Since normal WBCs and non-targeted tissues are unaffected, Leukothera® exhibits exceptional pharmaceutical ef�cacy in animal disease models with minimal negative side effects. Actinobac intends to initially develop Leukothera® for the treatment of hematological malignancies, psoriasis, and ocular in�ammatory disease.

EpiVax is an immunology company that has developed comprehensive analytical capabilities in the �eld of computational immunology. We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines. We leverage our proprietary tools and expertise, thereby adding value to our clients’ research and development efforts while applying them to our own pipeline of therapeutic proteins and vaccine candidates. EpiVax understands the scienti�c, �nancial, and regulatory challenges faced by today’s pharmaceutical industry and applies this knowledge at every step from design, to execution, to IND. EpiVax uses its scienti�c and technological assets related to epitope discovery, immunogenicity screening, de-immunization, and vaccine design through a mix of collaborative and internal programs.

WinSanTor, Inc. (WST) is a San Diego clinical stage company developing �rst-in-class therapies to prevent and reverse peripheral neuropathy. To date, there is no approved therapy for peripheral neuropathy, a neurodegenerative complication (of many diseases) suffered by 1 in 15 Americans. WST has identi�ed a class of compounds that promotes growth and plasticity of axon terminals, and reverse the neurodegeneration of the peripheral nerves damaged by a multitude of insults or injuries leading to peripheral neuropathy including diabetes, cancer, infectious disease and other induced and hereditary factors. WST’s lead compound (WST1 – a patented repurposed reformulation of a well-characterized oral drug for ulcers) is slated to begin Phase 1 trials in mid/late 2015 in Europe as a topical treatment for diabetic neuropathy, the largest subset of peripheral neuropathy associated with 50-70% of all diabetics.

9



sq. ft. of lab and

WuXi’s Dream

8.5” wide x 5.5” high.indd 1 2015/8/20 9:46:54

AfaSci, Inc., a San Francisco Bay Area biotech, commits to enhancing health care by conducting R&D into both Therapeutics and Biotechnology. AfaSci has developed and marketed the integrated modular platform-SmartCageTM for automated rodent behavior assays and in vivo higher-throughput drug screening. Taking advantage of our enabling technologies, AfaSci is developing two drug candidates for the treatment of neuropathic pain and neuroin�ammatory pain. Both candidates are novel non-addictive and non-steroidal analgesics. Competitive Advantage includes our drug candidates ready for IND-enabling studies, proprietary technologies, and in-house research capacity in electrophysiology and in vivo pharmacology. AfaSci has broad academic collaboration and is now seeking opportunities to advance these drug candidates to IND and clinical development through out-licensing, joint development, or outright acquisition.

TheraSource is an early-stage biotech company located in the New York City area. Our mission is to discover, develop, and commercialize novel protein and peptide biologics to treat human in�ammatory diseases. TheraSource has raised more than $12 million and received 14 Small Business Innovation Research (SBIR) awards from the NIH. We possess 13 patents covering 5 molecules. We have focused on developing our newly discovered human protein rhMFG-E8 to treat cardiac surgery-associated acute kidney injury (CSA-AKI). Every year, 395,000 Americans undergo cardiac surgery and 120,000 develop CSA-AKI. No drugs have yet been FDA-approved for this indication. TheraSource seeks strategic pharma partnerships and venture capital funding toward IND application and clinical development.

Giner Medical is a privately-held �rm specializing in electrochemical technologies for diverse �elds. Giner commercial products include oxygen generators for the U.S. Navy, hydrogen generators for analytical laboratories, transdermal alcohol sensors for the criminal justice market and hydrogen refueling stations for vehicles. Giner, Inc. (Medical Division) is developing an oxygenated cell implant platform for cellular therapies. The system will be fully implantable with a miniature oxygen generator that uses body water and power to generate oxygen. The provision of oxygen allows for high cell density implants of a practical size. Our �rst application will be the treatment of T1 diabetes without immunosuppression-- initially with human islets, and later with emerging sources of insulin-secreting cells including stem cells and xenogeneic cells.

Actuated Medical, Inc. (AMI) (Bellefonte, PA) was founded with a vision to integrate controlled actuation technologies into medical devices to improve patient outcomes. Our innovative motion devices solve clinical needs in different application areas; therefore, our products have variable exit strategies. AMI promotes capital ef�ciency by funding a majority of our early technology development through non-dilutive grants (e.g., SBIRs). We then use private funds to carry products to their respective exits (e.g., acquisition, licensing). Included in our business model are strong quality assurance, regulatory, reimbursement, and intellectual property strategies. AMI uses a FDA GMP compliant 7-stage product development cycle that is certi�ed ISO 13485:2003, and compliant to ISO 14971:2007. Learn more at ActuatedMedical.com, TubeClear.com, and GentleSharp.com.

BeTH has developed a patented novel human-device interface that improves comfort, mobility, and health, enabling the next generation of prosthetic and orthotic devices to achieve a custom �t without the cost of custom fabrication. Our �rst product application addresses a long standing challenge in prosthetic devices by allowing the wearer to easily and discreetly reduce pain caused by static sockets that cannot accommodate natural residual limb shape and volume changes. Our solution will not only alleviate pain but reduce the multiple visits and prosthetists (our customers) time and resources currently required to create a comfortable �t. BeTH's Class I medical device requires no FDA approval and will be sold to prosthetists under existing reimbursement codes.

480 Biomedical is a medical technology company focused on providing therapeutic solutions for adult and pediatric patients with vascular and respiratory conditions. We have created a pipeline of novel products based on our innovative bioresorbable implant technology platform. We utilize this unique technology to treat diseases locally while eliminating permanent implants. Our products transform medicine through innovations in materials science.

Regenerative medicine has the potential to transform standard of care in orphan diseases, cancer and diabetes; in this context, Feldan’s mission is to develop reagents and tools for cell and gene therapies. Protein-based technology Feldan Shuttle allows the delivery of proteins inside cells and precludes the use of viruses, electroporation and lipid-based transfectants, a feature allowing therapies to face less regulatory hurdles. Feldan Shuttle has applications in cell culture (by allowing the delivery of transcription factors to promote cell expansion, differentiation and reprogramming) and gene therapies (via its ability to deliver genome editing agents). Initially through strategic alliances but ultimately using its own platform, Feldan will catalyze its expertise in protein production and Shuttle Technology into novel cell therapies.

ViraCyte's goal is to eliminate deadly viral infections in immune compromised patients by use of virus killing T cell therapies. ViraCyte combines the T cell therapy expertise of Baylor College of Medicine's world renowned Center for Cell and Gene Therapy with the revolutionary proprietary G-Rex® T cell production platform of Wilson Wolf Manufacturing to create the world’s most advanced form of virus killing T cell therapy. The production platform can easily be transitioned to address a wide variety of infections and can deliver off-the-shelf products or custom products for each patient. Extensive clinical data demonstrates the clear superiority of ViraCyte’s solution when compared to standard care.

10


OrPro Therapeutics (JLABS, San Diego CA) is developing a non-systemic inhaled biologic drug platform for the treatment of Cystic Fibrosis (CF) and other obstructive diseases. OrPro’s technology is based on a naturally-secreted human airway enzyme engineered to ef�ciently normalize thickened mucus. This approach is genotype independent and supplements de�cient airway-surface activity. OrPro is working with leading academic CF experts and development partners with funding support from the Cystic Fibrosis Foundation and the National Institutes of Health. A scalable and cost-effective production process and aerosol-compatible formulation have been developed and proof of concept work in human cells and multiple animal models has established low in�ammatory risk and strong activity in CF patient sputum. Inhalation toxicology studies are ongoing with human trials expected in 2017.

OneVax LLC is a pre-clinical stage biotechnology company located in Gainesville, Florida committed to developing novel and effective therapies for type 1 diabetes and other auto-immune diseases. OneVax has developed a propriety biomaterial vaccine delivery platform consisting of subcutaneously injectable PLGA microparticles (MPs) loaded with immunomodulatory agents capable of restoring immune tolerance and ultimately curing type 1 diabetes. Non-phagocytosable MPs or self-assembling hydrogel ensure sustained release of select agents designed to create a tolerogenic microenvironment while phagocytosable MPs allow for uptake and subsequent tolerogenic presentation of speci�c antigens by antigen presenting cells. OneVax’s therapy is minimally invasive, requires no cell isolation and storage and, due to its stable composition, has an extended shelf-life, simplifying manufacturing and shipping.

Collagen Medical is developing targeted imaging probes to non-invasively detect blood clots and map organ �brosis using standard MRI and PET/CT scanners. Our goal is to transform personalized treatment planning by enabling physicians to make informed decisions based on a single imaging exam highlighting disease-speci�c pathology. The Company’s proprietary targeting technology has been extensively validated for the detection of blood clots (�brin targeting) and organ �brosis (type 1 collagen targeting). Our pipeline includes preclinical programs for the detection of blood clots in the setting of cryptogenic stroke (PET/CT) and for staging of organ �brosis using MRI. Collagen Medical is privately held and receives SBIR support from NIDDK, NHLBI, and NCI.

ODS Medical is bringing to market a revolutionary handheld optics probe which identi�es cancerous tissue in real-time during brain tumor surgery. This probe is as reliable as a trained pathologist and gives the surgeon the ability to �nd and remove areas of tumor that previously went undetected, all within a fraction of a second. More tumor removed means more effective surgeries, less recurrences and better outcomes for patients. Our patent protected Raman Spectroscopy technology has already been used in over 50 patients and was developed with input from key opinion leaders in neurosurgery. While we are pursuing regulatory approval for our lead neurosurgical product, we continue to develop the next generation of applications for a broad range of cancers.

Aquilus Pharmaceuticals is a biotechnology company specializing in the treatment and management of pain. The company will leverage its unique and proprietary platform of potent matrix metalloproteinase (MMP) inhibitors to develop medicines that will remove some of the root causes behind acute and chronic pain. Currently, the company has two preclinical programs: 1) an orally active MMP-2/-9 inhibitor to treat neuropathic pain and 2) an allosteric MMP-13 inhibitor to treat osteoarthritic pain and in�ammation (OA).

Magnetic Resonance Innovations, Inc. offers advanced quantitative magnetic resonance image processing software modules to analyze and quantify biomarkers for hospitals, radiologists, neurologists, neurosurgeons and imaging centers dealing with the diagnosis of neurovascular and cardiovascular diseases. Our software incorporates �ve sophisticated scienti�c algorithms for ef�cient and accurate quantitative assessment of cerebral microbleeds, iron content, white matter hyperintensities, blood �ow and perfusion in diseases such as dementia, multiple sclerosis, Parkinson's, stroke, and traumatic brain injury. The modules are user-friendly, reliable, fast, and allow rapid access to quantitative results. We have signi�cant skills in data processing, MR sequence research, clinical use for MRI, and internationally accepted protocol development making us an industry leader for major advances in medicine and new business opportunities.

Agile Sciences, Inc. is an emerging biopharmaceutical company, located in Raleigh, NC, that is pioneering an entirely new mechanistic approach for the treatment of antibiotic resistant, life-threatening infections. Agile Sciences’ core technology consists of a new class of 2-aminoimidazole (2-AI) small molecules that inhibit bacterial resistance mechanisms through a novel mode of action resulting in enhanced antibiotic activity. Agile Sciences is developing the 2-AI compounds for use in three therapeutic areas that involve dif�cult-to-treat, including multi-drug resistant bacterial infections, lung infections in cystic �brosis patients, and chronic wound infections. The Company supports its research programs through non-dilutive funding and to-date has secured over $12 million in grants and contracts.



JLABS

make the CONNECTION



WE WANT YOU!


sq. ft. of lab and

WuXi’s Dream

8.5” wide x 5.5” high.indd 1 2015/8/20 9:46:54

404-891-1750 | morleyresearchconsortium.com

Morley Research Consortium (MRC), a dedicated full service contract research organization (CRO) helps early to mid-stage medical device/biotech companies achieve their goals in getting products to commercialization. Our focus is different than most CROs since we only work with companies that are early to mid-stage who require regulatory planning and implementation (medical device and biotech), as well as, phase I – post marketing clinical trials.

MRC also currently works with venture capital, angel networks, and foundations to help screen new opportunities that align with funding criteria.

Having a solid clinical pathway and partner to bring your product to market is vital to your organization’s success. Look no further than MRC to turn the idea into reality.



JLABS

make the CONNECTION



WE WANT YOU!


sq. ft. of lab and

WuXi’s Dream

8.5” wide x 5.5” high.indd 1 2015/8/20 9:46:54


sq. ft. of lab and

WuXi’s Dream

13

EXHIBITING COMPANIES

Exhibiting Companies

Table 5 Table 8Table 7Table 6

Table 4Table 2 Table 3Table 1

Table 15 Table 16Table 14Table 13

Table 21 Table 22 Table 23

Table 27

Table 24

Table 25 Table 26

Table 9 Table 11 Table 12Table 10

Table 17 Table 18 Table 19 Table 20


sq. ft. of lab and

WuXi’s Dream

8.5” wide x 5.5” high.indd 1 2015/8/20 9:46:54

14

EXHIBITING COMPANIESTABLE 1 - 7

Life Science Nation (LSN) accelerates fundraising using its matching platform to create highly compatible relationships between early stage scientists/ entrepreneurs and emerging technology investors. LSN researches and curates market intelligence on two industry sectors. The �rst is emerging biotech and medtech companies, which by their ephemeral nature are challenging to �nd and track. Second, LSN tracks ten categories of early stage life science investors and identi�es who is �lling the void left by venture capital. LSN owns and operates the Rede�ning Early Stage Investments (RESI) conference series, which brings together global early stage biotech and medtech companies with early stage investors.

At Jameson & Company, we have helped businesses procure, manage and survive audit on more than $4 billion in government awards over the past three decades. We do business coast to coast, assisting over 120 clients in 27 states. Our team at Jameson & Company is comprised of senior level CPAs with more than 200 years of combined professional experience. We speci�cally work with companies utilizing SBIR/STTR, BARDA, R01, BAA and other government funding to keep them compliant and audit ready. We provide introductory services to either assist in setting up a proper accounting system, or an analysis to assess your current accounting system. Jameson & Company can help project your rates, negotiate with the government on your behalf, and represent you during your mandated audits.

The drug research and development process is highly complex, lengthy and expensive, yet essential for delivering safe and effective therapies to patients. Even though the process is reasonably well-de�ned, drug development programs are fundamentally different for each product, as the exact testing and submission requirements are shaped by many unique factors. To help our customers navigate this process, Charles River offers a wide range of products and services that span the entire drug discovery and development continuum and can be tailored to speci�c research conditions.

Morley Research Consortium (MRC) is a full service Contract Research Organization working primarily with early to mid-stage medical device and biotech/pharma companies on Phase I to Post-Market clinical trials. MRC offers companies currently seeking investment opportunities from funding sources no-cost preliminary evaluations on budgets and timelines needed for commercialization. MRC works with our extensive network of domestic and international clinical sites in over twenty four disciplines to ensure compliant, cost-effective, and timely studies. Positioned as a leader in clinical trials for early and mid-stage companies, MRC conducts clinical trials that satisfy all FDA requirements. When looking for a partner in all regulatory and clinical trial work, look no further than MRC.

GBBC provides services analyzing business operations of potential and existing investments made by investors in life science companies. The range of services start at the due diligence process of a potential investment opportunity through the management of investments leading to a successful exit strategy. GBBC provides insight into key functions of a medical device and biopharmaceutical startup and early growth stage businesses. The insight will assess a valuation for a business and optimize business operations to meet investor and company �nancial goals.

Atheln is a life science consulting �rm with over 60 industry seasoned experts. We provide project-speci�c virtual teams for hire. Each team includes all the disciplines required for the development of the particular product, including: non-clinical, CMC, quality, project management, regulatory, clinical, new product planning, business development and licensing, market access and reimbursement and others. The team creates strategies for risk control, designs integrated product development plans and manages plan execution for our clients. Our client solutions focus on approvability, manufacturability, reimbursability, fundability, and parterability of their technologies.

Minnetronix provides award-winning product design, development, manufacturing, and proprietary innovations to the medical device and life science marketplaces. Minnetronix’ experienced engineers and manufacturing teams provide expertise on a wide range of Class II and Class III medical equipment, including cardiovascular systems, point-of-care diagnostic instruments, therapeutic/drug delivery devices, implantable devices, and monitoring equipment. With over 220 employees, Minnetronix has led over 200 design and manufacturing projects for 125 different medical device and life science �rms, ranging in size from small start-ups to Fortune 100 companies. The company is FDA Registered, and ISO 13485 Certi�ed.


15

WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the US. As a research-driven and customer-focused company, WuXi provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec’s services are designed to help its global partners in shortening the cycle and lowering the cost of R&D. WuXi is also building a platform to provide clinical diagnostic and genomic services directly to physicians and their patients globally.

The NIH is the nation's medical research agency that supports scienti�c studies that turn discovery into health. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are one of the largest sources of early-stage capital for innovative small companies in the United States. In Fiscal Year 2015, NIH's SBIR and STTR programs will invest over 780 million dollars into early-stage, health and life science companies focused on advancing technologies towards the clinic. Twenty awardees of 5 of the NIH's Institutes and Centers have been selected to showcase their innovative technologies at this RESI conference. The participating institutes are: National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute of Neurological Disorders and Stroke.

The International Trade Branch assists Ontario companies in accessing international markets by establishing partnerships and distribution channels, and by providing assistance to foreign parties interested in sourcing Ontario products, technology and services. If you are an international buyer looking to source goods or services from Ontario, visit: SourceFromOntario.com.

American Research Capital, LLC (ARC) provides structured lending to companies performing work under grants and contracts sponsored by governmental payers such as the National Institutes of Health, Department of Defense, and other agencies. ARC delivers a working capital credit line for reimbursable expenditures designed to �t the needs of research, helping your company “bridge the gap” between spending on research activities and reimbursement from the payer. Financing from ARC accelerates your development timeline so you can achieve milestones faster, improve free cash �ow through faster contract reimbursement, and retain more ownership and control of your company by reducing the amount of equity capital you need to raise. ARC – Financing Designed for Research.

Created in 1979 by the healthcare technology industry, Medmarc’s purpose is to be the superior provider of liability insurance and related risk management solutions and to support the development, testing and delivery of products that save lives and improve the quality of life. Through our strategic alliances with The Hartford and clinical trial industry experts, we offer tailored insurance protection speci�cally designed for the broad spectrum of needs of the medical technology and life sciences industry. From ideas and prototypes to the reality of commercialization and success – We can Meet Your Changing Needs.

Kineta®, Inc., founded in 2007 by Drs. Charles Magness and Shawn Iadonato, is a biotechnology company focused on the development of new and novel therapeutic drug candidates. We are currently focused on autoimmune, antiviral and pain. Our lead drug, dalazatide, is phase II ready. We have a progressive business model aimed at accelerating advancement of novel medicines to bene�t patients and investors more quickly than traditional models. Kineta’s corporate strategy is to discover novel compounds, advance them through Phase I of the development process and then partner with larger biopharmaceutical companies to conduct late stage development and commercialization.

KPI Therapeutics (“KPI”) is a corporate development and funding consortium made up of Kineta, Inc. and several of its key strategic development partners. KPI’s operating model uses an asset-centric model, where each drug candidate family is separately developed and commercialized with our development and commercialization partners.



JLABS

make the CONNECTION



WE WANT YOU!

16


Ropack Pharma Solutions (RPS) is a competitive, full-service CMO for the North American market, providing contract solid oral dose formulation, process development, clinical and commercial manufacturing and packaging as well as distribution. We’re not just another CMO. We’re a trusted partner, collaborating with our clients to bring their vision to market. As an outsource partner, we act as an extension of our clients’ organizations. Demonstrating proven project management skills and proactive client engagement, our dedicated, multi-disciplinary teams keep projects moving forward reliably, expertly and on time. A 24/7 real-time client portal Keeps our client partners up-to-date on the progress of their projects. All services are performed in our state-of-the-art facilities which are cGMP-compliant and licensed by FDA and Health Canada.

McDermott Will & Emery is a premier international law �rm with a diversi�ed business practice. Established in 1934 as a tax practice in Chicago, Illinois, we have of�ces in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. McDermott has 80 years of serving a broad range of client interests. Our Life Sciences Industry Group is composed of 135 professionals, 60 with advanced science degrees and many others with government and industry experience, working across 19 of�ces around the world. With insights drawn from the only health practice ranked Tier 1 nationally by Chambers USA and our global reach, we deliver integrated business solutions to our clients, bringing the required experience from our leading tax, health, intellectual property, antitrust and regulatory practices to solve our client’s challenges.

As the world’s largest wealth manager, UBS is strongly positioned to address the realities of the global economy and a range of our clients’ sophisticated needs. For over 150 years, UBS has been helping individuals, entrepreneurs and their families pursue their goals by providing a combination of wealth management, investment banking and asset management services. Customized solutions are delivered by dedicated Financial Advisors who focus intently on your speci�c needs. Our clients have direct access to �nancial experts from UBS Investment Bank and Wealth Management at locations across the globe, including a broad array of solutions from both the private and the corporate side. As the world's largest wealth manager and one of the best capitalized banks in the industry, UBS has consistently ranked among the world's top �nancial institutions and was recently named “Best Global Wealth Manager” 2015 by Euromoney.

DavosPharma provides discovery services, custom chemistry (novel raw materials, GMP intermediates, regulatory starting materials & APIs), biologics, and custom dosage forms (parenterals and orals), with supporting development, analytics, stability and regulatory documentation. We have successfully leveraged forty years of custom manufacturing experience, forming global strategic alliances with well-vetted, cGMP custom manufacturers in the EU, North America and Asia. Our expertise enables us to match your particular need with the supplier best able to deliver your project. DavosPharma shares your risk by billing for deliverables, not best efforts, providing an additional level of assurance and oversight between you and the supplier.

The O'Connor Law Of�ce provides comprehensive transactional legal services and counsel to entrepreneurs and business ventures at all stages of their life cycles. We provide strategic, and practical, legal support, partnering with our clients to turn innovation into a thriving business operation. We work with venture-backed technology companies as well as U.S subsidiaries of foreign ventures to �rst-time entrepreneurs. We help these entrepreneurs from inception to anticipate, address and develop strategies to manage the legal risks that affect their businesses.

TriNet is a leading provider of a comprehensive human resources solution for small to medium-sized businesses. We enhance business productivity by enabling our clients to outsource their human resources, or HR, function to one strategic partner and allowing them to focus on operating and growing their core businesses. Our HR solution includes services such as payroll processing, human capital consulting, employment law compliance and employee bene�ts, including health insurance, retirement plans and workers compensation insurance. Our services are delivered by our expert team of HR professionals and enabled by our proprietary, cloud-based technology platform, which allows our clients and their employees to ef�ciently conduct their HR transactions anytime and anywhere.

M2D2 is a joint project between University of Massachusetts Lowell and University of Massachusetts Medical School. M2D2 operates two innovation centers for both medical device and biotech entrepreneurs including (7) private labs dedicated to medical device start-up companies located at 600 Suffolk Street, Lowell MA and an 11,000 square foot shared biotech lab with shared equipment at 110 Canal Street, Lowell MA. Only 3 blocks from the MBTA commuter rail station, M2D2 offers affordable lab and of�ce space to Boston and Cambridge entrepreneurs. They are also able to take advantage of all M2D2 and the University of Massachusetts have to offer. M2D2 internal capabilities include assistance with establishing business in Massachusetts, business plan writing, market research, grant writing, pitch coaching, access to investors, engineering & design support, prototyping, clinician feedback and review, clinical trials, and animal trials.



JLABS

make the CONNECTION



WE WANT YOU!

17

INTRODUCING CRADL™ -

THE CHARLES RIVER ACCELERATOR AND DEVELOPMENT LAB

The Charles River Accelerator and Development Lab (CRADL™) is our new option providing turnkey vivarium rental space in Kendall Square, Cambridge, MA. This centrally-located laboratory allows clients to invest in their research projects instead of infrastructure, without compromising on the quality of their workspace or equipment. Managed by our skilled technicians, animals

receive the best in care in secure, modern, compliant facilities. CRADL™ is the optimum space for our clients to launch or expand their business, with the added

of integrated drug discovery resources.

For more information, visit us at www.criver.com.

675 W. Kendall Street, Cambridge, Massachusetts

www.criver.com.

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation’s most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences.

Triumvirate Environmental is a leading provider of enterprise waste management and environmental services to Healthcare, Education, Life Sciences, and Industrial markets. Triumvirate can help with a wide-range of services from reducing environmental waste to implementing safer and more compliant waste management practices. Triumvirate offers only highly educated, expertly trained consultants with years of experience. That's why the most demanding universities, hospitals, biotech �rms, pharmaceutical manufacturers, and industrial companies choose Triumvirate Environmental.

AdvaMed 2015 is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international �avor and featuring a deep, diverse attendee list that includes in�uential policy-makers, business executives and media, AdvaMed 2015 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more. It is a “must-attend” event for any MedTech company.

Arxspan provides superior cloud-based solutions to meet the scienti�c data management needs of leading life sciences companies globally. Arxspan offers a suite of web-based informatics applications, including electronic laboratory notebook (ELN), chemical/biological registration, assay registration, inventory management, and decision support for project-based research & development data management and collaboration. Users can track internal research, manage incoming CRO data, and integrate Arxspan’s web-based, platform-independent user interface with existing enterprise knowledge management tools. Arxspan is expert at developing and hosting robust, secure, and 21 CFR Part 11 compliant web-based scienti�c software application systems, making Arxspan an ideal hosting partner for research, intellectual property, and other proprietary and con�dential data.

Helping technology-driven companies grow and succeed is an ongoing commitment of Dilworth IP. Often, the most valuable asset of any early-stage company is its intellectual property. Leveraging these assets by developing a sophisticated IP strategy, including protection in the form of patents, trademarks, and copyrights, can make or break a company’s ability to secure vital investment. Similarly, as an enterprise grows its need to generate revenue can be furthered along via licensing and other commercial agreements. Dilworth IP has a particular focus on servicing the life science industry and our recently launched incentive program for start-ups is particularly designed for such technology-driven companies to help them achieve their goals through compensation incentives for legal services.

Venture Valuation specializes in independent assessments and valuations of companies in high-growth markets, such as biotechnology, life sciences and medical technology. Venture Valuation offers independent company valuations for fund raising as well as product valuations for licensing deals.

Halloran Consulting Group is a management consulting �rm that partners with life science companies to guide them through today’s complex clinical, quality, and regulatory landscape. Halloran works with industry organizations of all types, including biotech, pharma, medical device, and life science service providers, to provide tailored solutions and advance product development. We are proud to be a WBENC certi�ed woman-owned business. Please visit our website, www.hallorancg.com, for more information about our expert solutions, team expertise and to see what Halloran can do for you.

EXHIBITING COMPANIESTABLE 21- 27

INTRODUCING CRADL™ -

THE CHARLES RIVER ACCELERATOR AND DEVELOPMENT LAB

The Charles River Accelerator and Development Lab (CRADL™) is our new option providing turnkey vivarium rental space in Kendall Square, Cambridge, MA. This centrally-located laboratory allows clients to invest in their research projects instead of infrastructure, without compromising on the quality of their workspace or equipment. Managed by our skilled technicians, animals

receive the best in care in secure, modern, compliant facilities. CRADL™ is the optimum space for our clients to launch or expand their business, with the added

of integrated drug discovery resources.

For more information, visit us at www.criver.com.

675 W. Kendall Street, Cambridge, Massachusetts

www.criver.com.

19

INVESTOR PANELS TRACK 1Track 1

ModeratorM

Sponsored by:

Track 1 Moderator & Panelists

8:00 - 8:50 AM

9:00 - 9:50 AM

10:00 - 10:50 AM

11:00 - 11:50 AM

1:00 - 1:50 PM

2:00 - 2:50 PM

3:00 - 3:50 PM

4:00 - 4:50 PM

BIOTECHAngels

Preclinical & phase I

investors

bigpharma

BIOTECHfamily offices

PHASE II & PHASE IIIINVESTORS

CorporateVenture capital

funding & RESOURCESFOR STARTUPS

venturephilanthropy

M

M

M

M

M

M

M

M

• Donnie McGrath, VP of Business Development, Bristol-Myers Squibb• Ann DeWitt, Senior Director of Investments, Sano�-Genzyme BioVentures• Edward Hu, CFO & CIO, WuXi AppTec• Mark Powers, CFO, Integrium• Martin Heidecker, Director & Investment Manager, Boehringer Ingelheim Venture Fund

• Janice Bourque, Managing Director, Life Sciences, Hercules Technology Growth Capital• Alex Zisson, Partner, Thomas, McNerney & Partners• Anton Gopka, CEO & General Partner, ATEM Capital• Cynthia Lavoie, General Partner, TVM Capital• Frank Gentile, Entrepreneur in Residence, Third Rock Ventures

• Pravin Chaturvedi, Founder, TiE Angels• Jeffrey Arnold, Member, Boston Harbor Angels & Mass Medical Angels• Jennifer Seibert, CEO, GAP Ventures• Mic Williams, President, Boston Harbor Angels• Richard Anders, Co-Managing Director, Mass Medical Angels

• Bill Brah, Founder & Executive Director, UMass Venture Development Center• Alexander Pickett, Associate, Mediqventures• Jayson Rieger, SVP of Business Development & Portfolio Management, PBM Capital• Rick Jones, Director, Broadview Ventures

• Steve Yoder, Global Head, Specialty Pharmaceuticals Search & Evaluation, BD, Bristol-Myers Squibb• Kiran Reddy, Senior Director, Corporate Strategy, Biogen Idec• Kuldeep Neote, Senior Director, New Ventures/Scout, Johnson & Johnson Innovation• Michael Draper, Senior Director External Science & Partnering – East Coast, Sano�• Tomas Landh, Vice President, Senior Principal Scientist Innovation Sourcing, Novo Nordisk

• Todd Haim, Program Director, SBIR Development Center, NCI• Jennifer Shieh, Small Business Coordinator & Program Director, NHLBI• Jonathan Franca-Koh, Program Director, SBIR Development Center, NCI• Stephanie Fertig, Research Project Manager, Small Business Programs, NINDS• Timothy Hsiao, Small Business Innovation Specialist, NIAID

• Christopher de Souza, Director, Broadview Ventures• Daniel Smith, VP of Innovative Technologies, Autism Speaks• David Sandak, VP, Strategy & Research, Accelerate Brain Cancer Cure• Jit Patel, VP of Research & Business Development, JDRF• Usha Arunachalam, VP, Business Development for Research, Leukemia & Lymphoma Society

• Steve Gullans, Managing Director, Excel Venture Management• Arjun Goyal, Associate, 5AM Ventures• Isai Peimer, Managing Director, MedImmune Ventures• Jayson Punwani, Principal, Pappas Ventures• Sam Hall, Principal, Apple Tree Partners







21

INVESTOR PANELS TRACK 2Track 2

Sponsored by:

ModeratorM

Track 2 Moderator & Panelists

8:00 - 8:50 AM

9:00 - 9:50 AM

10:00 - 10:50 AM

11:00 - 11:50 AM

1:00 - 1:50 PM

2:00 - 2:50 PM

3:00 - 3:50 PM

4:00 - 4:50 PM

MEDTECHangels

Medical DEVICEINVESTORS

medtechstrategics

tales fromthe road

Diagnosticinvestors

healthcare itinvestors

Globalinvestors

medtechfamily offices

M

M

M

M

M

M

M

M

• Colin Widen, CEO, Boston Innovation Capital• Alejandra Paredones, CEO & Founder, BSI Capital• Maria Berkman, Director, Broadview Ventures• Oded Levy, Managing Partner, Blue Ox Capital• Ron Paliwoda, President, The Paliwoda Group

• Lisa Rhoads, Managing Director, Easton Capital• Christopher Kim, Managing Partner, Korea-Seoul Life Science Fund• Luis Barros, Managing Partner, Leading Business Ventures & Venture Partner, Portugal Capital Ventures• Weiyong Sun, Senior Director, External Scienti�c Affairs, Daiichi Sankyo Group• Winston Town, Vice President, Diamond BioFund

• Barbara Gamez Sims, Technology Licensing Manager, Mayo Clinic Ventures• Aaron Nelson, General Partner, dRx Capital• Gabe Ling, Venture Partner, General Catalyst• Hyuk-Jeen Suh, Head of East Coast Of�ce, Samsung Ventures• Michael Jin, Managing Partner, TEEC Angel Fund

• Parker Cassidy, Executive in Residence, RA Capital Management• Bob Williams, VP of Business Development & Innovation, Bracco Diagnostics• Charles Moehle, VP of Business Development & Licensing, Illumina• Joe Cunningham, Managing Director, Santé Ventures• John Steuart, Venture Partner, Prolog Ventures

• Richard Berenson, CEO, Thermalin Diabetes• Davis Brimer, CEO, Founder, Director, ActiveLife Scienti�c• Paul Molloy, President & CEO, ClearFlow• Shantanu Gaur, Co-Founder & CSO, Allurion Technologies• Zoë Barry, Founder & CEO, ZappRx

• Steve Goodman, Co-Founder, Mid Atlantic Bio Angels• David Verrill, Founder & Managing Director, Hub Angels Investment Group• Mike Harsh, Limited Partner, Golden Angel Investors• Patricia Gray, Member, Mass Medical Angels• Richard Yules, Vice President, New World Angels

• Joe Cunningham, Managing Director, Santé Ventures• Dana Callow, Managing Partner, Boston Millennia Partners• Geoff Pardo, Partner, Gilde Healthcare Partners• Juan Carlos Serna, Vice President, Health Policy Associates• Yumin Choi, Partner, HLM Venture Partners

• Jeffrey Barnes, Managing Director, Bioventures Investors• Charlie Attlan, Senior Vice President, Corporate Business Development, Boston Scienti�c• Gwen Watanabe, VP of Business Development & Technical Resources, Tele�ex• Ibraheem Badejo, Senior Director, New Ventures, Johnson & Johnson Innovation• Jake Giannotti, Senior Director, Corporate M&A and BD, Philips Health Systems

22

biotech angelstrack 1 panelists8:00 - 8:50 am

Track 1

• Pravin Chaturvedi, Founder, TiE Angels

Dr. Chaturvedi is a serial entrepreneur and angel investor in the life sciences community. He is the Founder of Boston-based IndUS Pharmaceuticals and the co-founder of Florida-based Oceanyx Pharmaceuticals and serves as the Chief Executive Of�cer of both these organizations. He has also served as the President & Chief Scienti�c Of�cer of San Francisco-based Napo Pharmaceuticals and prior to that was the President and Chief Executive Of�cer of Boston-based Scion Pharmaceuticals. Dr. Chaturvedi serves on the boards of IndUS, Oceanyx, FuelEd Schools, Cellanyx, PRADAN USA and Sindu Research Laboratories and has previously served on the boards of Scion Pharmaceuticals and TiE Boston. He is the Chairman of the SAB for Pivot Pharmaceuticals and serves as an advisory board member to Springboard Enterprises and the Research Advisory Council for the Health Sciences Center of West Virginia University. He is also an adjunct faculty member at Georgetown Medical School. Over his 25+ year career, Dr. Chaturvedi has participated or led the discovery and/or the development activities for several new chemical entities (NCEs), culminating in the successful development and commercialization of several new drugs that are currently marketed by various companies. Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in Pharmacy from the University of Bombay.

M

• Jeffrey Arnold, Member, Boston Harbor Angels & Mass Medical Angels

Mr. Arnold is the president of Arnold Strategies, LLC, a strategic advisor to early and growth stage CEO's, and an angel investor with Mass Medical Angels and Boston Harbor Angels. As an angel investor, Mr. Arnold, has invested in, among others, SmartCells (sold to Merck), BioAssets development Corp (sold to Cephalon), Syntonix (sold to Biogen Idec), Health Honors (sold to Healthway) and JB Therapeutics (now public as Corbus Pharmaceutical Holdings). Prior to founding Arnold Strategies, Mr. Arnold spent 20 years as the CEO of multiple private and public technology and life science companies. Among these include Cambridge Heart, a cardiology diagnostics company which he founded and took public, CardioFocus, a VC backed catheter ablation company and Accelrys, a public company with software tools for rational drug design, now a division of Dassault Systemes. Mr. Arnold is a guest lecturer at the MIT Sloan School, mentor at the MIT Venture Mentoring Society, on the Grant Review Board of the MIT Deshpande Center and on the Board of Overseers at the Museum of Science. He was formerly Chairman of the Greater Boston Chapter of the American Heart Association. He received a BSEE from MIT in 1972.

• Jennifer Seibert, CEO, GAP Ventures

Jennifer Seibert is an experienced entrepreneur and angel investor in life science technology and related business and �nancial matters. Jennifer is a Managing Director of Golden Seeds, ranked by the Angel Capital Association as the most active investment groups in early stage start-ups. She has 20+ years’ experience in pharmaceutical and diagnostic product development, sales/marketing, licensing & M&A for biotech companies and employers YM BioSciences (Gilead), Univ. Chicago, Abbott Laboratories, Amgen Inc., and Biosource International (Invitrogen). She earned MBA in Finance from Northwestern University, M.Sc. in Biochemistry from Drexel University and B.S. in Chemistry from University of Delaware.

• Richard Anders, Co-Managing Director, Mass Medical Angels

Richard Anders is is an investor and long-time entrepreneur. He founded the legal software publishing company Jurisoft, which he sold to Lexis/Nexis, published newspapers including Boston Digital Industry and New York Digital Industry and currently serves as managing director of Rubin/Anders Scienti�c, which places scientists as consultants in patent projects. He has invested in approximately two dozen early-stage startups. Richard is a long-time trustee of the Museum of Science in Boston, where he is a member of the food committee, exploring science education around the issues of food and its preparation, a trustee of the Forsyth Institute and an overseer at the Gardner Museum. Richard founded and currently runs MA Medical Angels (MA2), one of the country's leading angel groups focused exclusively on life sciences. He has founded the angel group Launchpad, the nationally renowned Science on Screen event at the Coolidge Corner Cinema and was a founding trustee of the Massachusetts Interactive Media Council. He served for many years as a member of the Dana Farber Cancer Center Institutional Review Board. He is a board observer at Avaxia Biologics and Siamab. Richard teaches medical device entrepreneurship at the Harvard/MIT HST program. He is a graduate Summa Cum Laude in Mathematics from Harvard and holds a J.D. from Harvard Law School.

• Mic Williams, President, Boston Harbor Angels

Mic (Michael) Williams has been an investor for over 35 years. Whereas his primary investments and have been in commercial real estate; his previous private investments have included manufacturing, mining, movies, lumber products, ships and a television enterprise. He founded Boston Harbor Angels eleven years ago and has invested in 25+ deals. He has had several very successful exits with Smart Cells (Merck $500MM and Carbonite-IPO, Corbus Pharmaceuticals Holdings Inc.CRBP NASD,) There are more than several auspicious horses still in his barn while some of the others have been rendered. Mic has served on many, public, private, and charitable boards. He spent 18 years with Coldwell Banker Commercial Group starting in sales through Senior Management serving on the Board. He opened up commercial group of�ces in NY, NJ and Ct. He left to join Aries Enterprises as President of a large scale land development company in Colorado and Arizona. He was involved in the planning, development and sales of major planned communities. He was a Managing Director of Landauer (a NY real estate consulting �rm) and also provided real estate investment banking services with a small private �rm in NYC.

23

Preclinical & phase I investorstrack 1 panelists9:00 - 9:50 am

Track 1

• Steve Gullans, Managing Director, Excel Venture Management

Steve Gullans, Ph.D., is an author, scientist, entrepreneur, and biotech investor. He is a Managing Director at Excel Venture Management where he invests in life science companies with transformative technologies. Previously Steve co-founded and held senior executive roles at biotech companies. Currently he is a Director at Molecular Templates Cleveland HeartLab, and Orionis Biosciences and he previously was a Director at Tetraphase Pharmaceuticals [TTPH] and other successful startups. Steve loves innovation and has spoken widely, including at TED and TEDx. He and Juan Enriquez recently co-authored Evolving Ourselves, a book that provides a sweeping tour of how humans are changing the course of evolution—sometimes intentionally, sometimes not. Previously he was a professor at Harvard Medical School where he published more than 130 scienti�c papers and was elected Fellow of the American Association for the Advancement of Science. Steve lives in Boston where he enjoys working with young entrepreneurs, playing golf and tennis, and teaching his granddaughter to say, “We want ice cream sandwiches for lunch.”

M

• Arjun Goyal, Associate, 5AM Ventures

Arjun Goyal, MD, joined 5AM Ventures in 2014. Prior to joining 5AM Ventures, Arjun was co-founder of Foresight Pharmaceuticals, a company developing hormonal treatments for sexually transmitted infections. Dr. Goyal currently serves as an Observer on the Board of Cleave Biosciences. He trained in internal medicine through the University of Sydney hospital system and is the author of several patents. Earlier in his career, he served as an analyst in global health policy at the Australian Mission to the United Nations. Dr. Goyal holds a B.S. in Medical Science, a Diploma in French and an M.D. from the Universities of Melbourne and Oxford, a M. Phil from the University of Cambridge and a MBA from Harvard Business School, where he was a Kaplan Life Science Fellow and an American Australian Association Fellow. Dr. Goyal is based in the Waltham, MA of�ce.

• Isai Peimer, Managing Director, MedImmune Ventures

Isai joined MedImmune Ventures in 2010. He is currently or has been a board member of Adheron, Ambit (NASDAQ: AMBI, acquired by Daiichi Sankyo), Armaron, Corridor (acquired by Astrazeneca), Inotek (NASDAQ:ITEK), and Xencor (NASDAQ: XNCR). He serves on The Ivy Foundation Biomedical Innovation Review Board at University of Virginia. Previously, Isai worked as a venture capitalist at Visium Asset Management. He was an investment banker at J.P. Morgan and a Specialty Pharmaceuticals analyst at Alliance Bernstein. Prior to Wall Street, Isai was a management consultant in the pharmaceutical and biotech industry; he began his career as a scientist at Merck. Isai is a graduate of Emory University where he earned a B.A. in Chemistry summa cum laude, and earned his M.B.A. from the Tuck School of Business at Dartmouth.

• Sam Hall, Principal, Apple Tree Partners

Sam Hall has over a decade of experience in the life sciences across roles as a private equity investor, investment banker and basic scientist. Prior to joining Apple Tree in 2013, he was a researcher at the University of Cambridge in the UK, where his work focused on novel therapeutic strategies for autoimmune diseases. Previously, Sam was a member of the investment team at Symphony Capital, a private equity �rm dedicated to investments in biopharmaceutical development. Prior to Symphony, he served as a member of the healthcare investment banking team at Citigroup, where he advised leading biotechnology, medical device and healthcare services businesses on numerous completed strategic and debt and equity �nancing engagements. Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.

• Jayson Punwani, Principal, Pappas Ventures

Jayson Punwani joined Pappas Ventures in 2011 and is responsible for evaluating investment opportunities, performing due diligence and monitoring portfolio positions. He is currently a board observer at Aura Biosciences, Balance Therapeutics, CardioDx, CoLucid Pharmaceuticals and OrphoMed. Prior to joining Pappas, Jayson conducted research in signal transduction pathways as a postdoctoral fellow at UNC-Chapel Hill. He also worked at the Of�ce of Technology Development at UNC, where he developed and executed commercialization and licensing strategies for life science technologies.

24

BIOTECH family officestrack 1 panelists10:00 - 10:50 am

Track 1

• Bill Brah, Founder & Executive Director, UMass Venture Development Center

Bill has played an integral role on the University of Massachusetts economic development team, responsible for the emergence of the university as a national leader in research, development and technology transfer. Since 2000, University of Massachusetts income from technology licenses and spin-off companies has increased to place the university among the top 10 in the nation. Research expenditures also have been growing at a rate that signi�cantly exceeds the national average. This growth is a result of a multi-year, multi-faceted effort by the economic development team to expand the University's role as a Massachusetts innovation engine. During this period, Bill Brah served as a special assistant to the vice president of economic development in the president's of�ce, then came to the Boston campus as assistant vice provost for research and created the Venture Development Center, an award winning life sciences incubator, which he now heads. In the past 18 months, startup companies at the center have raised over $35M in seed �nancing, the best results in Boston.Bill began his career at the National Oceanic and Atmospheric Administration. He earned a master's degree in business administration and oceanography from the Mays School of Business at Texas A&M University.

M

• Alexander Pickett, Associate, Mediqventures

Alexander Pickett is an associate at Mediqventures. Prior to joining Mediqventures, he was an associate at Flatley Venture Capital, a cystic �brosis focused investment arm of a family of�ce, where he was responsible for investment analysis and scienti�c due diligence. While there, he also supported Flatley Discovery Lab's business development efforts. Alexander co-founded Real Life Sciences, a start-up focused on using software-based patient-engagement solutions in order to improve patient recruitment to clinical trials. Prior to joining Flatley Venture Capital, Alexander graduated from Harvard College with an A.B. in Molecular and Cellular Biology, where he was a Microbial Studies Initiative Undergraduate Fellow and an International Genetically Engineered Machines Competition Team Member.

• Jayson Rieger, SVP of Business Development & Portfolio Management, PBM Capital

Dr. Jayson M. Rieger, Ph.D, MBA, is currently the SVP of Business Development & Portfolio Management for PBM Capital, LLC, where he supports new investment evaluation, deal sourcing and provides technical and business support for portfolio companies. Dr. Rieger has more than 10 years experience in cross-functional scienti�c and business leadership roles spanning business development, research operations, drug discovery and product development in the life sciences industry. Most recently he served as Corporate Senior Vice President and President of the Human Therapeutics Division at Intrexon Corporation. Dr. Rieger has also served as the Vice President of Research and Virginia Operations for Clinical Data, Inc., prior to its acquisition by Forest Labs in 2011. Dr. Rieger served as the Vice President of Lead Development at Adenosine Therapeutics, LLC, from prior to its acquisition by Clinical Data in 2008. Dr. Rieger has delivered a number of invited lectures at universities and scienti�c conferences and has served as a key team member in multiple development programs ranging from discovery stage research to Phase III clinical trials. He was the recipient of more than 10 federal grants, serving as both principal and co-investigator on efforts targeted towards evaluating adenosine receptor agents in a variety of disease indications.

• Rick Jones, Director, Broadview Ventures

Frederick “Rick” Jones, MD, shares responsibility for the day-to-day operations of Broadview Ventures, including identi�cation and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement. Prior to joining Broadview Ventures, Rick founded Spordiff Therapeutics, which is developing a small molecule to prevent C. dif�cile infection. Previously, Rick was CEO of Anchor Therapeutics, a venture-backed company developing a platform of lipidated peptides targeting intractable GPCR targets. Before that Rick held increasingly responsible positions as a general manager, business development professional and medical affairs of�cer with Devgen, BioRexis and Wyeth Pharmaceuticals. Early in his career, Dr. Jones practiced internal medicine, most recently as Assistant Professor in the University of Pennsylvania health system. Rick earned his undergraduate, medical and MBA degrees from the University of Pennsylvania. Rick currently serves as the Board Observer for Aggamin, Remedy, Ischemia Care and ZZ Biotech.

25

big pharmatrack 1 panelists11:00 - 11:50 am

• Steve Yoder, Global Head, Specialty Pharmaceuticals Search & Evaluation, BD, Bristol-Myers Squibb

Stephen E. Yoder, MD, MBA is Head, Specialty Pharmaceuticals Search and Evaluation in Bristol-Myers Squibb Business Development. He has responsibilities for leading a team of Search & Evaluation Global Leads who identify and conduct initial assessments and diligence evaluations of cardiovascular, �brosis, genetically de�ned and rare diseases, and immunoscience licensing and acquisition opportunities. Dr. Yoder initially joined BMS in 2012 as Global Lead, CV-Metabolic Search & Evaluation from his previous position as Senior Director, Strategic Planning at P�zer’s Worldwide Research & Development Division, where he held earlier roles in Corporate Strategic Planning, New Product Development and Worldwide Marketing. He was also a Principal at Easton Associates, and worked as a consultant in the healthcare practice of Arthur D. Little. Dr. Yoder received a B.S. from Bucknell University and M.D. from the University of Virginia. He subsequently obtained an M.B.A. in Health Care Management from the Wharton School.

• Kiran Reddy, Senior Director, Corporate Strategy, Biogen Idec

Kiran Reddy is a Senior Director in the Corporate Strategy/Capita group at Biogen Idec. At Biogen Idec, Kiran is focused on sourcing new technologies and product opportunities to support the Company's growth via acquisitions, partnerships, and equity investments. Prior to Biogen Idec, Kiran was an Associate Partner at Third Rock Ventures, where he supported and managed various portfolio companies in addition to focusing on new company formation and due diligence. He was founder and interim Chief Business Of�cer for SAGE Therapeutics through its IPO. Kiran was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara pharmaceuticals, Rhythm pharmaceuticals, and PanOptica pharmaceuticals. Before Third Rock Ventures, Kiran was a management consultant at the Lewin Group within in the biotechnology and pharmaceutical practice, and advised clients on clinical development and commercial strategy. Kiran holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard / Massachusetts General Hospital and is a board certi�ed neurologist. Kiran was previously a Howard Hughes science fellow, and has authored several peer-reviewed scienti�c papers in the �eld of neuroimmunology and neurodegenerative diseases.

• Kuldeep Neote, Senior Director, New Ventures/Scout, Johnson & Johnson Innovation

Kuldeep Neote, Ph.D., is Senior Director at J&J Innovation Center-Boston, and is responsible for New Venture and Scouting opportunities in the areas of Oncology and Immunology in the East Coast. Dr. Neote is trained as a Molecule Biologist with an extensive background in drug discovery. He has been focused in the area of Immunology, In�ammation and Oncology and has a passion for implementing cutting edge scienti�c discoveries into practical drug discovery programs. Throughout his career, he has looked at creative scienti�c and business development collaborative and partnering opportunities that have resulted in tangible clinical translation of new scienti�c discoveries working in conjunction with academic and biotech companies. Formerly, Dr. Neote was Research Advisor/Director in Global External R&D at Eli Lilly in Indianapolis, IN. Prior to Eli Lilly, he was a Discovery Scientist in P�zer Inc. in Groton, CT. Dr. Neote initiated the Chemokine Receptor Drug Discovery platform that lead to several clinical candidates, and also discovered novel chemokines. Earlier in his career, Dr. Neote cloned one of the �rst chemokine receptors during his post-doctoral studies in Genentech.

• Michael Draper, Senior Director External Science & Partnering – East Coast, Sano�

Dr. Michael Draper is currently the Senior Director of External Science and Partnering and a member of the Science, Strategy & External Innovation and Science Policy group at Sano�. He has more than 15 years of research and development experience in the pharmaceutical industry at both large and small pharmaceutical companies. After completing his postdoctoral studies, he joined the organization that later became Aventis Pharmaceuticals as a Senior Scientist. In 2000, he joined Paratek Pharmaceuticals. During his time at Paratek, he managed discovery, clinical operations, and regulatory affairs and advanced multiple compounds into the clinic. He has been the Principal Investigator for Phase I and II SBIR grants and an Investigator on a Bill and Melinda Gates foundation grant to discover new tetracyclines for �lariasis. Dr. Draper has held several adjunct faculty positions throughout his career. He received his M.S. degree from the University of Connecticut and his Ph.D. in Genetics from the University of New Hampshire. He conducted his postdoctoral work at Tufts University with Dr. Stuart Levy. He has his Regulatory Affairs Certi�cation and is an inventor on multiple patents. In his current role at Sano� he is responsible for setting up partnerships with major academic and medical institutions, biotechnology companies, and disease foundations.

• Tomas Landh, Vice President, Senior Principal Scientist Innovation Sourcing, Novo Nordisk

Tomas Landh is since 2008 Director (Strategy and Sourcing) at Novo Nordisk, Diabetes Research Unit, where he is responsible for the scouting and evaluation of in particular, protein therapeutics and related technologies including new drug delivery systems for the treatment of diabetes, its complications and obesity. Besides seeking innovation in these areas, Tomas is involved in developing new strategic modes of accessing innovation in general. Two years after joining Novo Nordisk in 2003, Tomas was recruited to the Diabetes Research Unit with scouting and evaluation of external technology opportunities for oral delivery of proteins as his main responsibility. Prior to joining Novo Nordisk, Tomas was R&D Director and Chief Scientist at Camurus AB (1997-2002), a lipid drug delivery company and CEO for Lipid Research Foundation (2001-2003), a foundation sponsoring applied lipid research. He received his PhD in Biophysical Engineering from Lund’s Institute of Technology. Tomas has + 20 years of experience of all stages of drug development and delivery, ranging from academia, small businesses, foundations and big pharma/biotech.

M

Track 1

26

PHASE II & PHASE III INVESTORStrack 1 panelists1:00 - 1:50 pm

Track 1

• Janice Bourque, Managing Director, Life Sciences, Hercules Technology Growth Capital

As a managing director in the Life Science Group, Janice Bourque has more than 25 years of life science experience and focuses on emerging growth stage life science companies. Before joining Hercules in 2010, Bourque advised and provided strategic corporate investor fundraising for Commons Capital and Oxford Bioscience Partners to create a global health fund focused on innovative healthcare investments for emerging and developing countries. She also was senior vice president and group head-life sciences for Comerica Bank for 4 years beginning in 2005. In addition, Bourque led the Massachusetts Biotechnology Council (MBC), the �rst biotechnology association in the world, for 12 years as President/CEO. Bourque held several other senior managerial positions, including CFO/controller of Cambridge Medical Technology Corporation, senior public accountant for Coopers & Lybrand Emerging and Middle Market Group, and project manager for NASA Space Science at UNH. Bourque holds an M.B.A in �nance and accounting and B.S. in veterinary science from the University of New Hampshire. She currently serves on the board of directors of The Village Bank, Commodore Builders, and the Hyde CDC; is an advisor to TBS Technologies, Trustee for Specialized Housing; co-President of the Crystal Lake Conservancy and a member of the Women’s Forum.

M

• Alex Zisson, Partner, Thomas, McNerney & Partners

Alex has been with Thomas, McNerney & Partners since its �rst fund was raised in 2002. He currently serves on the board of directors for Auspex Pharmaceuticals, Clarus Therapeutics, and Keystone Dental. Alex is a member of the Industry Advisory Board of the Children’s Tumor Foundation, and a board member of Advanced Medical Research Institute of Canada Development Corporation (AMRIC-DC), which is focused on economic development in northern Ontario. He is also an advisor for the Partnership Fund of NYC, which manages a bioaccelarator to advance local healthcare research and is on the Life Sciences Council for Springboard Enterprises, a group that assists female entrepreneurs. Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor �rms Chase H&Q and JPMorgan). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex also became the �rm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey.

• Anton Gopka, CEO & General Partner, ATEM Capital

Anton Gopka is a CEO and General Partner at ATEM Capital managing an evergreen US Biotech Fund - Health Square Fund. Prior to ATEM Mr. Gopka was managing one of the largest Russia-based biotechnological venture capital funds - a US$760 million strategic partnership between RUSNANO and Domain Associates where he made over 10 private investments into high-pro�le US biotech development companies and managed public offerings of 3 companies on NASDAQ. Before that Mr. Gopka was a Vice President at Barclays Capital where he took part in a major Russian Power Utilities restructuring. Prior to Barclays Capital he was a Director of M&A at Sistema JSFC, the largest diversi�ed conglomerate in Russia where he led landmark transactions in Telecoms and Oil&Gas sectors. Mr. Gopka started off his investment banking career at Dresdner Kleinwort, where he advised on a number of M&A and capital markets transactions worth over US$10bn in total. Current and previous board memberships include Marinus Pharmaceuticals, Regado BioSciences, CoDa Therapeutics, Neothetics, Tragara Pharmaceuticals, NovaDigm Therapeutics and Revision Optics (observer), Syndax Pharmaceuticals (observer), Miramar Labs (observer).

• Frank Gentile, Entrepreneur in Residence, Third Rock Ventures

Frank Gentile joined Third Rock Ventures in 2015 to focus on research and development opportunities throughout the portfolio. Franks brings nearly 25 years of experience working with pharmaceutical and biotechnology companies, and spent the past 12 years with Tekla Capital Management LLC, formerly Hambrecht & Quist Capital Management LLC, where he most recently served as senior vice president. In this role, Frank oversaw and executed biotechnology and healthcare investments in public and private companies in the areas of oncology, cardiovascular, infectious diseases, rare diseases, medical devices and diagnostics and discovery tools and served as a member of the board of directors in several private companies. Prior to Tekla, Frank held roles of increasing responsibility at Millennium Pharmaceuticals, Curis, Reprogenesis, Inc., and CytoTherapeutics, Inc. He currently serves as an adjunct associate professor of pharmacology and biotechnology in the division of biology and medicine at Brown University. Frank completed his post-doctoral work at the Swiss Federal Institute of Technology in Zurich and received his Ph.D. in chemical engineering from MIT where he was a G.E. Fellow.

• Cynthia Lavoie, General Partner, TVM Capital

Dr. Lavoie is a General Partner with TVM Capital Life Science, an international venture capital �rm with more than $1 billion under management. Dr. Lavoie is responsible for deal making, deal origination and execution and for the management of portfolio companies in the US and Canada. Dr. Lavoie has led investments into Montreal-based TVM companies Kaneq Bioscience and FAAH Pharma, where she serves on the Boards of Directors. Dr. Lavoie also serves on the board of Acer Therapeutics, located in Cambridge, MA. Prior to TVM, Dr. Lavoie was with VG Partners, a large Canadian private equity �rm, where her most recent role was as Partner and head of life sciences. She served on the boards of therapeutics and device companies including Cytochroma (sold to Opko Health) and Trillium Therapeutics (TSX: TR). Dr. Lavoie also had a direct role in the sale of VisualSonics, an imaging company, to SonoSite Inc. (now Fuji�lm SonoSite). Previously, Dr. Lavoie was a marketing strategy consultant with drug/device developer Vasogen (merged with Intellipharmaceutics; NASDAQ: IPCI). Dr. Lavoie completed her PhD at McGill University and carried out academic and commercially focused research at the University of Texas Southwestern Medical Center.

27

Corporate Venture capitaltrack 1 panelists2:00 - 2:50 pm

Track 1

• Donnie McGrath, VP of Business Development, Bristol-Myers Squibb

Donnie McGrath is Vice President, Business Development at BMS. He has been working in academic medicine and the life sciences sector for 19 years. His global team is responsible for all search and evaluation and due diligence activities for BMS. He works with senior R&D and commercial leadership to design and execute the business development strategy for BMS. He joined the Virology Global Clinical Research group of Bristol-Myers Squibb in 2005. He was the Reyataz® Development Lead until joining the Business Development group in 2010. Prior to joining BMS he was a staff physician in the infectious disease department at Tufts-New England Medical Center in Boston. He received his medical training in Dublin, Ireland, and in Boston, Massachusetts. He has an MPH degree from Harvard University School of Public Health.

M

• Ann DeWitt, Senior Director of Investments, Sano�-Genzyme BioVentures

Ann joined SGBV in 2013 with a background in biotech partnering and early stage investment. Prior to SGBV, Ann was Senior Director, Corporate Development at Permeon Biologics and also a Senior Associate at Flagship Ventures. Before HBS, she worked at 3M Company in corporate research and in business units, including 3M Pharmaceuticals, and was a Technical Circle of Excellence Award winner. Ann holds a Ph.D. from MIT in systems biology, and an M.B.A. from Harvard Business School, and she is on the Life Sciences Council of Springboard Enterprises, an organization dedicated to building high-growth technology-oriented companies led by women.

• Edward Hu, CFO & CIO, WuXi AppTec

Mr. Edward Hu, is currently Chief Financial Of�cer & Chief Investment Of�cer at WuXi AppTec. In this capacity, Mr. Hu manages WuXi’s �nance, strategic investments, merger and acquisition, and new business building. In addition, He also manages WuXi’s joint ventures with MedImmune and PRA. Mr. Hu is Head of WuXi Corporate Venture Fund, spearheading the fund’s investment strategy and portfolio management. Previously, he served as WuXi’s Chief Operating Of�cer and Chief Financial Of�cer. Prior to joining WuXi, Mr. Hu was SVP and Chief Operating Of�cer at Tanox, responsible for operations, �nance, IT, project management and strategic planning, and managed the acquisition of Tanox by Genentech in 2007. He also held positions at Merck & Co., Inc. as a Senior Financial Analyst and later in Business and Financial Planning Manager at Biogen, Inc. (n/k/a Biogen Idec, Inc.), where he managed the business planning of Biogen's R&D and clinical development programs, and provided project planning and analysis support to key drug development project teams. Mr. Hu completed his Ph.D. work, all but dissertation, in Biophysics and Biochemistry at Carnegie Mellon University, where he also received his MBA degree.

• Martin Heidecker, Director & Investment Manager, Boehringer Ingelheim Venture Fund

Martin joined the Boehringer Ingelheim Venture Fund in 2010 to invest in early innovative therapeutic life science companies. In October 2013, Martin established the US-of�ce of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. Prior to BIVF, Martin held several global roles in Marketing at Boehringer Ingelheim and Solvay Pharmaceuticals and was involved in the global launch of several products in the area of CNS. Martin began his career as an Investment Manager at Bayern Kapital, focusing on seed investments of biotech companies. Martin holds a PhD in Biology as well as a Master degree in Biology and Economics. He serves on the board of AMP Therapeutics GmbH and ArmaGen Technologies, Inc.

• Mark Powers, CFO, Integrium

Mark Powers is a Managing Director at Integrium Clinical Research. Mr. Powers joined Integrium in 2011, with over 25 years of operational experience and �nancial leadership in the �elds of healthcare, technology, and investment banking. Mr. Powers was formerly President and currently a Director on the Board of CallSource, LLC. Prior to joining Call Source, he was Managing Director of New Capital Advisors. Mr. Powers has executed banking transactions, merger and acquisitions transactions, and held operational positions in technology healthcare and consulting sectors. Powers earned his B.A. from UCLA, and is based in Los Angeles, California.

28

NIH funding & RESOURCES FOR STARTUPStrack 1 panelists3:00 - 3:50 pm

• Todd Haim, Program Director, SBIR Development Center, NCI

Dr. Todd Haim is a Program Director at the National Cancer Institute’s Small Business Innovation Research (SBIR) Development Center. Dr. Haim manages SBIR & STTR grants and contracts focused on the development of novel cancer therapeutics, preventative agents, and drug discovery technologies that incorporate the tumor microenvironment. Additionally, Todd plays a key role in the planning, design, and leadership of several center initiatives, including serving as coordinator of the NCI Investor Forum, helping to implement relevant workshops, draft targeted solicitations, and facilitate external partnerships. Prior to starting in the SBIR Development Center, he was a Research Associate and Christine Mirzayan Science and Technology Policy Fellow at the National Academy of Sciences. Dr. Haim staffed the Committee on Science, Engineering and Public Policy (COSEPUP) and his efforts centered on follow-up activities to the 2005 “Rising Above the Gathering Storm” report related to various innovation initiatives and evaluation programs. Previously, he completed a postdoctoral fellowship at P�zer in which he actively led P�zer’s research efforts in a collaboration with Washington University School of Medicine in St. Louis that illustrated a mechanism for altered cardiac contractility due to excess fatty acids. Dr. Haim graduated from Albert Einstein College of Medicine in January 2007 with a PhD in biomedical research and obtained a certi�cate in technology commercialization from John Hopkins’ Carey Business School in 2011. He has received several prestigious awards and honors including the 2014 NCI Leadership Development Award, a 2014 NIH Director’s Award and the NJ Governor’s Award for Volunteerism in the Field of Health.

M

• Jennifer Shieh, Small Business Coordinator & Program Director, NHLBI

Dr. Jennifer Shieh helps small businesses commercialize technology focused on heart, lung, blood, and sleep disorders through the Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) programs at the National Heart, Lung, and Blood Institute (NHLBI) Of�ce of Translational Alliances and Coordination. Previously, she was a Program Director at the National Cancer Institute (NCI) SBIR Development Center, having joined NCI as an AAAS Science and Technology Policy Fellow. She was involved in product and customer development at Syapse, a precision medicine-focused startup, and mobile games startup Subversus Interactive. Dr. Shieh studied brain and cognitive sciences at MIT, then earned her PhD in neurosciences at Stanford University. She is co-author of the textbook Guide to Research Techniques in Neuroscience.

• Jonathan Franca-Koh, Program Director, SBIR Development Center, NCI

Dr. Jonathan Franca-Koh is a Program Director at the National Cancer Institute's Small Business Innovation Research (SBIR) Development Center. Jonathan manages SBIR & STTR grants and contracts with a focus on cancer therapeutics and novel tools for research and drug discovery. He provides oversight throughout the award period and mentors applicants and awardees in developing their technology goals and commercialization strategy. Additionally, he plays an active role in several center initiatives, including recent investor forums, workshops, targeted funding opportunities, and represents the NCI on the trans-NIH REACH program. Prior to joining the SBIR Development Center, Jonathan was a Program Director at the NCI Division of Cancer Biology and Center for Strategic Scienti�c Initiatives, overseeing the Physical Sciences-Oncology Centers (PS-OC) program, a network of interdisciplinary centers that brought together physical scientists and cancer biologists. Jonathan received his PhD in Cell and Molecular Biology from the University of London’s Institute of Cancer Research in 2003, and completed post-doctoral research at Johns Hopkins University and the J. Craig Venter Institute. In 2014 he completed his MBA from Johns Hopkins University, focusing on �nance and health care innovation.

• Stephanie Fertig, Research Project Manager, Small Business Programs, Of�ce of Translational Research, NINDS

Stephanie J. Fertig is the research project manager for small business programs in the Of�ce of Translational Research at the National Institute of Neurological Disorders and Stroke (NINDS). Ms. Fertig manages both the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which are congressionally mandated set-aside programs speci�cally for small business concerns. In addition, she also manages the Cooperative Research to Enable and Advance Translational Enterprises (CREATE) program for therapeutic devices. Prior to her position in the Of�ce of Translational Research, she was a member of the Repair and Plasticity cluster in the NINDS Division of Extramural Research. Before coming to NINDS, Ms. Fertig worked as a researcher in the Center for Bio/Molecular Science and Engineering at the Naval Research Laboratory (NRL) in Washington D.C. Ms. Fertig has a B.S. degree in Chemistry with a major in Physics from the University of Virginia and an M.B.A. from the University of Maryland's Robert H. Smith School of Business.

• Timothy Hsiao, Small Business Innovation Specialist, NIAID

Tim helps develop and manage programs to strengthen the $120 million plus (annual)-portfolio of federal investment in small business innovation research/small business technology transfer (SBIR/STTR) through National Institute of Allergy and Infectious Diseases (NIAID). He is af�liated with NIAID’s Of�ce of Research Training and Special Programs at the Division of Extramural Research. Prior to NIAID, Tim was awarded the AAAS Science & Technology Policy Fellowship, and served both the Economic Section of the U.S. Embassy (Mexico City) as an Innovation Policy Of�cer and the U.S. Agency for International Development as an Innovation Management Advisor. Tim holds a Ph.D. in Molecular Biophysics & Biochemistry from Yale University.

29

venture philanthropytrack 1 panelists4:00 - 4:50 pm

Track 1

• Christopher de Souza, Director, Broadview Ventures

Christopher de Souza, PhD, shares responsibility for the day-to-day operations of Broadview Ventures, including business development strategy, identi�cation and screening of new investment opportunities, negotiation of partnering terms and deal structure, as well as portfolio company board involvement. Christopher started his pharmaceutical career at Novartis where he was a senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances with responsibilities for the therapeutic area strategy, business development and alliance management. After Novartis, Christopher was VP of Business Development at SkyePharma US Inc, a drug delivery company, where he was responsible for out-licensing SkyePharma’s clinical assets and drug delivery technologies. Christopher also founded a business development consulting practice with several clients including JSB-Partners, Diagnostics For All and Metaome. Christopher received an MBA from Rutgers University and a PhD in physiology from Louisiana State University. He completed his post-doctoral training at “The Upjohn Company” and the Joslin Diabetes Center/Harvard Medical School.

M

• Daniel Smith, VP of Innovative Technologies, Autism Speaks

Dan is the Vice President, Innovative Technologies at Autism Speaks and President of Delivering Scienti�c Innovation for Autism LLC, a venture philanthropy af�liate of Autism Speaks. Dan is a neuroscientist by training and has a decade of experience as a senior neuroscience researcher, laboratory head and project leader in the pharmaceutical industry. In his current roles, he is responsible for creating and managing a portfolio of projects and investments focused on identifying and delivering evidence-based solutions to the healthcare and quality of life challenges faced by people with autism and their families. Dan’s purview includes cutting-edge early-stage technology and biomedical research and development projects, philanthropic venture investment, business development and partnering opportunities with the for-pro�t sector.

• David Sandak, VP, Strategy & Research, Accelerate Brain Cancer Cure

David Sandak is Vice President of Strategy & Research at Accelerate Brain Cancer Cure, a venture philanthropy that invests in translational brain tumor research. Since brain cancer affects a relatively small portion of the population, David and his team work in the early stages of the discovery and development pipeline in order to "buy down the risk" to speed progress of innovative new treatments to the clinic. David manages the organization's academic research grants and leads Accelerate Brain Cancer Cure's seed investment fund, which has backed companies such as Agios and Tocagen. He is currently working to launch a social enterprise to advance genomic analysis for cancer patients. With his corporate, government and non-pro�t management background, David is keenly adept at forging collaborative partnerships between researchers from academia, government and bio-pharmaceutical companies. Prior to Accelerate Brain Cancer Cure, David worked as a policy analyst in Washington, led a Congressionally chartered think tank, and worked in corporate strategy at Xerox. He is a graduate of Colby College.

• Usha Arunachalam, VP, Business Development for Research, Leukemia & Lymphoma Society

Dr. Usha Arunachalam is Vice President for Business Development, Research at the Leukemia Lymphoma Society. At LLS she assists the research team in all research investments (TAP and Grants). She has over 17 years of business development experience, primarily with early staged biotechnology companies. Previously, she was SVP, Corporate Development at IndUS Pharmaceuticals (US/India based company) a start-up, where she helped merge the assets of Applied Protein Sciences into IndUS. Prior to this, Dr. Arunachalam was VP of Business Development and led the business development and strategic efforts of FivePrime Therapeutics. At Fiveprime she was an integral member of the executive team and was instrumental in raising more than $ 120 MM in near term investments for collaborative research from strategic partners, primarily large Pharmaceutical companies. Prior to joining FivePrime, she served as Vice President, Business Development at Intrabiotics and served as a member of the executive team. Prior to joining Intrabiotics, Dr. Arunachalam was Sr. Director of Business development at Kosan Biosciences, where she was responsible for all in- and out-licensing and business development activities for multiple projects. Dr. Arunachalam received her Ph.D in Biochemistry from the Indian Institute of Science and received a pre-doctoral fellowship from University of Michigan to work on her thesis. She received her MBA from UCLA's Anderson School of Management.

• Jit Patel, VP of Research & Business Development, JDRF

Dr. Jit Patel is Vice President of Research & Business Development at Juvenile Diabetes Research Foundation (JDRF). JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to facilitate development of novel therapeutics to better treat and cure type 1 diabetes and its complications. Currently JDRF is currently sponsoring more than $568 million in research, advocacy and development in 17 countries. As head of Research Business Development, Dr. Patel is responsible for establishing and managing strategic, mission-aligned industry R&D partnerships with biopharmaceutical and medical device companies. Dr. Patel obtained his B.Sc. and PhD from Kings College, University of London. He did his postdoctoral training at the NIH, and subsequently joined AstraZeneca Biopharmaceuticals. After holding several key leadership positions with increasing responsibilities in drug discovery, Dr. Patel transitioned to pursue a career in business development. As a scientist, Dr. Patel has authored more than 80 scienti�c papers and edited two books in Neuroscience. As a business development professional, he has executed a substantial number of strategically transformative deals across the R&D value chain and industry sector.

30

MEDTECH ANGELStrack 2 panelists8:00 - 8:50 Am

• Steve Goodman, Co-Founder, Mid Atlantic Bio Angels

Stephen M. Goodman is a co-founder of Mid Atlantic Bio Angels, an angel investor group focused on early-stage life science companies and 1st Pitch Life Science, a public forum. He has mentored numerous life science and technology start-ups through the Lang Center for Entrepreneurship at The Eugene Lang Entrepreneurship Center at Columbia Business School and the E-Lab for Life Science Entrepreneurs sponsored by the New York City Economic Development Corporation. Mr. Goodman is also a partner and co-head of the Mergers and Acquisitions Practice at Pryor Cashman LLP in New York City. His clients include drug development and diagnostic companies, medical device companies, clinical trial management companies and companies in other technology businesses.

M

• David Verrill, Founder & Managing Director, Hub Angels Investment Group

David’s professional career began as a research scientist at the Center for Blood Research in Boston focusing on the MHC of genetically engineered mice. After receiving his master's degree from Sloan in 1987, he spent a decade at MIT raising capital from industry and facilitating technology transfer. David still holds a partial appointment at MIT’s new Initiative on the Digital Economy. In 1996 he joined Xerox as Manager of International Sales and Business Development for the Adaptive Products Division before it was sold. In 1998 David joined third party marketing �rm Winchester International Group as Managing Director. In 2000 Winchester helped found the Hub Angels, a series of early stage investment funds in Boston (US). David sits on several startup Boards (Viral Gains, Content Raven, Geezeo), and is Chairman Emeritus of the Angel Capital Association. He is one of XConomy’s “Top Angel Investors in New England”. David was educated at Bowdoin College and the MIT Sloan School of Management.

• Mike Harsh, Limited Partner, Golden Angel Investors

Mike is a Limited Partner at Golden Angel Investors and the co-founder of Terapede Systems, a digital x-ray detector startup. He is also a member of the Board of Directors of FloDesign Sonics, a company that utilizes ultrasound for bioprocess �ltration, and Endra, that has unique technology for thermoacoustic enhanced ultrasound imaging. Mike is a member of the Scienti�c Advisory Board of Phoenix Nuclear labs and a consultant to start-ups in the medical device industry. He served as GE Healthcare’s Vice President and Chief Technology Of�cer, leading the global Science and Technology Organization and its research and development teams in diagnostics, healthcare IT, and life sciences prior to retiring in January 2015. Mike was appointed to this position in 2009. He also served as Vice President and Executive Advisor for GE Ventures. Mike is a graduate of Marquette University in Milwaukee, Wisconsin, where he earned a bachelor’s degree in Electrical Engineering. He holds numerous U.S. patents in the �eld of medical imaging and instrumentation.

• Patricia Gray, Member, Mass Medical Angels

Pat Gray is an active angel investor, board member and venture advisor with a particular interest in health care and the life sciences. She has been a business plan judge, guest executive and lecturer on board governance, securities and corporate law, published articles on Directors’ and Of�cers’ Responsibilities in Reorganization and corporate takeover laws, and was named one of the “In�uential Women in Wireless” by Wireless Week, a recognized trade publication. Pat is currently member of the Board of Directors or Advisors of early stage companies in water puri�cation, life sciences therapeutics and telemedicine. Prior board and advisory service included companies involved with health care, threat detection/security, telecommunications and retail. Earlier in her career, Pat was General Counsel for HealthCare Ventures Funds, where she did legal work associated with over 60 life science venture investments. Pat was also an executive and general counsel for multiple publicly traded companies, including American Science & Engineering, Inc., The Children’s Place Retail Stores, Inc., Panera Bread, and Arch Wireless, Inc. and an attorney at major Wall Street law �rms. Pat is a member of Mass Medical Angels, Boynton Angels and The Boston Club. She holds a JD degree Georgetown University Law Center and BA from Cornell University.

• Richard Yules, Vice President, New World Angels

Doctor Yules is presently a member of the Board of Governors of the FAU Foundation and Vice President of New World Angels, a 50 member Florida angel investment group. He has served as a consultant and board member of public and private companies in the medical and biotechnology arenae. He retired a Brigadier General and ANG Assistant to the Assistant Secretary of Defense for Health Affairs. The Doctor served as the founder and Managing Director of Haelen Medical Center for 20 years, the Chairman of the Worcester City Hospital EENT Department for 13 years, and an FAA Class I Aviation Medical Examiner and Senior Crash Investigator for 24 years. He was educated at Yale University where he received both his BA and MD degrees, at Stanford University for his general and plastic surgery residency, and at Harvard University for his ENT residency. He maintains a Harvard Medical School position as the MSLO. Board certi�ed in otorhinolaryngology since 1971, Dr. Yules is a fellow in many of his 31 professional societies. He has held numerous NSF grants, spoken at, and instructed at and/or attended over 150 medical or administrative meetings. He has published over 50 manuscripts including 4 books. He has been consultant to the USAF Surgeon General, a member of numerous panels, and chairman of or advisor to numerous committees.

Track 2

31

Medical DEVICE INVESTORStrack 2 panelists9:00 - 9:50 am

Track 2

• Joe Cunningham, Managing Director, Santé Ventures

Joe Cunningham is a Founding Partner and Managing Director of Santé Ventures, an early-stage life science and healthcare venture capital company based in Austin, Texas. Prior to this Joe was a healthcare Venture Partner with Austin Ventures and was previously the Vice Chair of the Ascension Health Ventures investment committee. He is also the former Chief Medical Of�cer of the Providence Health System and Executive Director of the 300-physician Providence Health Alliance, both of which belong to the Ascension Health system. He has extensive management experience and is recognized nationally for his expertise in healthcare delivery systems, physician associations and compensation models. Joe serves on Advisory Boards for both United Healthcare and for Health Services Corporation (BC/BS). He is board certi�ed in both Internal Medicine and Quality Assurance and Peer Review. Dr. Cunningham received his BS and MD degrees from Texas A&M University and his MBA from Baylor University.

M

• Geoff Pardo, Partner, Gilde Healthcare Partners

Mr. Pardo joined Gilde Healthcare Partners in 2011 as a Partner, and has led investments in InovaLabs, iWalk and Vapotherm and serves on the boards of those companies. Previously, he was a Partner at Spray Venture Partners where he led investments into Interlace Medical (sold to Hologic), Solace Therapeutics and TearScience and Cascade Ophthalmics. He served on the board of Solace, TearScience and Cascade, and was actively involved in Interlace and Conventus Orthopedics. Mr. Pardo also served as President & CEO of Facet Solutions, a spinal implant company focused on treating lumbar spinal stenosis until the company was sold to Globus Medical in 2011. Mr. Pardo has also worked at Cardinal Partners as an Associate leading their investing activity in the medical device sector. Mr. Pardo began his career in medical devices as a product manager with Synthes USA. Geoff has a B.A. from Brown University and an M.B.A. from the Wharton School of Business.

• Juan Carlos Serna, Vice President, Health Policy Associates

Mr. Serna has over a 15 experience leading international medical device companies through preclinical and clinical development, clinical trials, regulatory affairs, and quality assurance. He currently serves as Vice President of Health Policy Associates Inc., a strategy, clinical and regulatory consulting group in Westwood, MA. Health Policy Associates Inc. offers extensive best-practices experience in medical device regulations, Good Clinical Practices (GCP), Quality System Regulations (QSR), Good Clinical Data Management Practices (GCDMP), Good Laboratory Practices (GLP), and execution of FDA and CE mark regulatory submissions across a broad span of therapeutic areas. Mr. Serna is also a Partner at HPA Ventures, where he raises and manages investment funds focused on medical device companies and identi�es new businesses and provides support for portfolio companies. Mr. Serna holds an A.B. from Dartmouth College in Biology and Philosophy and a graduate degree in Business Administration from Babson College.

• Yumin Choi, Partner, HLM Venture Partners

Yumin is currently a director of AbilTo, Spinal Kinetics and Vets First Choice. He is a board observer at IHM Services and Nordic Consulting. He previously was a board observer of TYRX (acquired by Medtronic). Yumin is a director to The Capital Network, a non-pro�t focused on educating entrepreneurs around topics of fundraising and �nance. He previously was chair of the New England Venture Network (NEVN), the largest young Venture Capital organization in New England. Yumin is co-chair of the Boston Symphony Orchestra Venture Capital and Private Equity committee and is on Boston University’s Coulter Foundation Oversight Committee. Prior to HLM, Yumin was with Angel Healthcare Investors, a health care focused early stage investment group, ZweigWhite’s Financial Advisory Services and Mergers & Acquisitions Group and was co-founder and CEO of CY Digital. He is also a mentor in health care focused startup accelerators, Blueprint Health, Healthbox, and StartUp Health, and is an active angel investor. Yumin also holds an appointment as Lecturer in the Gordon Institute at Tufts University where he teaches a course in Entrepreneurial Finance. Yumin received a BS from Babson College.

• Dana Callow, Managing Partner, Boston Millennia Partners

Mr. Callow is the Managing Partner of Boston Millennia Partners. Prior to founding BMP, Mr. Callow co-founded Boston Capital Ventures. He is currently Presiding Director and Chair of the governance committee of PAREXEL International Corp. He is, or has served, as a Director of a number of other companies including Ilex Oncology, Inc., MedAptus, Inc., and PHT, Inc. He is a member of the Board of Trustees and past Chairman of the Investment Committee at Tufts University and on the Board of Overseers at Tufts University Medical School. Mr. Callow is a National Board Member for the Leukemia & Lymphoma Society and chairs the Therapy Acceleration Program committee. Mr. Callow is a graduate of Tufts University and holds an MBA from the Amos Tuck School at Dartmouth College.

32

medtech family officestrack 2 panelists10:00 - 10:50 pm

Track 2

• Colin Widen, CEO, Boston Innovation Capital

Colin Widen is a seasoned executive with 25 years of sales, trading and portfolio management experience in major investment banks. In 2001, Colin left the institutional world and founded W.A.M. Asset Management, a private equity fund of funds that focused on SBIC private equity funds. After selling the �rm to a larger fund of funds, Colin joined Deutsche Bank where he led a team providing consulting services about alternative asset allocation strategies to family of�ces and smaller endowments and foundations. Colin is a registered representative with StillPoint Capital and holds Series 7, 24, 63 and 82 registrations. His specialties include reconstructing hedge fund portfolios and analyzing private equity holdings.

M

• Alejandra Paredones, CEO & Founder, BSI Capital

Alejandra is a global entrepreneur with extensive Investment & Leadership experience -responsible for the strategic vision, direction and structured growth of BSI Capital. She started off her career with Lighthouse Realty in San Diego, California - where she executed acquisitions and rentals of of�ce buildings, residential & commercial, and managed real estate portfolio for global institutional clients. Moreover, she also worked in the legal and international affairs area for the OAS (Organization of American States) in Washington DC headquarters. Additionally, she worked as a Campaign Advisor for the Hillary R. Clinton 2008 Presidential campaign. Extending her career to Switzerland, she worked as a Private Strategist for numerous HNWI/UNHWI from Latin America, overseeing an overall $1.5B in AUM. Ms. Paredones declined offers from Wall Street �rms, and decided to engage in other opportunities of her own, by founding in 2011 BSI Capital Group. Ms. Paredones is considered the �rst women in Mexico under the age of 30, to have developed a successful global boutique Investment Bank & Venture Capital Group. In the last years, she has led and executed complex M&A transactions & Private Placements, positioning BSI as a leader expert in their region.

• Maria Berkman, Director, Broadview Ventures

Maria Berkman, MD, shares responsibility for the day-to-day operations of Broadview Ventures, including identi�cation and screening of new opportunities, due diligence, negotiation of deal structure, as well as portfolio company board involvement. Prior to joining Broadview Ventures Maria was a management consultant for Monitor Group, where she specialized in life sciences with a focus on biopharmaceutical corporate strategy, franchise and asset-level commercialization strategy, and competitive strategic planning. Before joining Monitor Group, Maria completed Transitional Year training within the Partners HealthCare System at Newton Wellesley Hospital, splitting her time between Internal Medicine and General Surgery. Maria earned her MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in the surgical subspecialties, at the intersection of cardiothoracic and trauma surgery. Maria earned her MBA from the Anderson School of Management at UCLA. Her undergraduate degree in Psychology is from New York University. Maria currently serves as the Board Observer for Apama, BioKier, Cardialen, InfoBionic, Vascular Graft Solutions and Zumbro Discovery.

• Ron Paliwoda, President, The Paliwoda Group

Ron Paliwoda in an accidental entrepreneur and seasoned investor, primarily through the �rm he founded 20 years ago, The Paliwoda Group. This privately held �rm targets early-stage projects with intellectual property that complement its existing business divisions, products and technologies. In the healthcare sector, it uses the Health Tech Fund to focus on projects that can reduce healthcare costs by improving operational ef�ciencies at service providers, and by empowering healthcare consumers to better manage the cost of their treatment. Ron advises talented teams with novel approaches to solving big challenges, including projects in the medical technology space like Genotype Diagnostics, who use machine-learning systems to better understand how genetic variation can lead to disease; and BioArray, who streamline personal health monitoring by converting complex data into clear insight. Ron is actively involved in issues that concern the environment, health and excellence in education, and is a passionate advocate for supporting early-stage innovation by offering local working environments where startups are nurtured, and high-potential leaders are continuously challenged to excel. He holds degrees from the University of Michigan in Psychology, Anthropology, and Zoology, and may be found on any given Saturday during College Football season cheering for his beloved Michigan Wolverines.

• Oded Levy, Managing Partner, Blue Ox Capital

Oded Levy has over 25 years of experience investing in public and private companies. He is the Founder and Managing Partner of Blue Ox Capital, LLC. He currently serves as co-CEO of Delphi Health Group, LLC and on the Board of Directors of Delphi and In�nity Funding, LLC, both investments of Blue Ox. He was also mostly recently Executive Chairman of portfolio company MedSave USA until its sale in September 2013. From 1999 to 2005, Mr. Levy was a Principal with Oracle Partners, LP, a private investment �rm specializing in public securities investing and merchant banking in the Healthcare, Bioscience and related industries. The �rm managed approximately $1 billion of capital in investment partnerships funded by institutional investors, healthcare executives and private investors. Prior to 1999, Mr. Levy was a partner with Will K. Weinstein, managing Jackson Square Partners, LP, a $100 million hedge fund headquartered in San Francisco. While at Jackson Square, he focused on investing in special situations. From 1994 to 1998, Mr. Levy was a Partner, member of the Executive Committee, and the Head Trader at Genesis Merchant Group Securities (“GMGS”); a San Francisco based investment bank. With over $30 million in revenues, GMGS was consistently ranked in the top 50 institutional brokers.

33

medtech strategicstrack 2 panelists11:00 - 11:50 am

Track 2

• Ibraheem Badejo, Senior Director, New Ventures, Johnson & Johnson Innovation

Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University. During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired. Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.

M

• Charlie Attlan, Senior Vice President, Corporate Business Development, Boston Scienti�c

Charlie Attlan is the Senior Vice President of Corporate Business Development at Boston Scienti�c. He leads the business development initiatives for the corporation with responsibility for mergers, acquisitions, licensing, divestiture and VC investing activities. Charlie has over 20 years of experience in the merger and acquisition space. Prior to joining Boston Scienti�c in 2010, he was a Director, Healthcare Mergers and Acquisitions for Credit Suisse. Prior to that role, he held various investment banking positions at Credit Suisse, DLJ and Bankers Trust, in New York, Chicago and Paris. Charlie holds a BA degree from Princeton University.

• Gwen Watanabe, VP of Business Development & Technical Resources, Tele�ex

Gwen Watanabe is the Vice President of Corporate Business Development and Strategy Group for Tele�ex Incorporated. Ms. Watanabe came to Tele�ex through their acquisition of Hotspur Technologies, Inc, where she served as its President and Chief Executive Of�cer since 2009. Prior to this, Ms. Watanabe co-founded Nellix, Inc. and served as its Chief Business Of�cer from inception to 2009. served as a Founding Team Member at Bacchus Vascular, where she served as the Business Development and Marketing Manager. She served as also a Founding Team Member at AneuRx, where she was an Engineer for the stent-graft delivery system team and co- inventor . Ms. Watanabe also has a private equity background as she was a managing partner at Lava Management, LLC and a General Partner at Saratoga Ventures.. Ms. Watanabe has served as a Director at Sleep Solutions (Novasom), PracticeFusion, Axis Surgical, and Catharos Medical. In August 2008, she was inducted into the Cambridge Who's Who Registry. Ms. Watanabe holds an M.S. in Mechanical Engineering from Stanford University in the Design Division with an emphasis on Biomechanical Design and an M.B.A. from Harvard Business School with focus on Finance and Marketing. Ms. Watanabe also holds a B.S. in Mechanical Engineering from Massachusetts Institute of Technology.

• Jeffrey Barnes, Managing Director, Bioventures Investors

Jeff is a Managing Director at BioVentures Investors and has over 30 years of start-up, operating and investment experience in the life sciences and healthcare sectors. Before joining BioVentures, Jeff was a General Partner at Oxford Bioscience Partners. While there, he was responsible for building and leading the �rm’s investment strategy in medical devices and diagnostic instrumentation, and originated and managed investments in 18 portfolio companies. He has been instrumental in the successful acquisition of seven medical device companies to strategic acquirers including Edwards Lifesciences, Medtronic, ThermoFisher, Boston Scienti�c and Olympus Corp. Prior to venture capital, Jeff spent eight years in investment banking within the healthcare groups of Needham & Co. and Robertson, Stephens & Co. In addition, he also has over 12 years of operating experience, including management positions in research and development, manufacturing, and marketing within the Medical Products Group of Hewlett-Packard Corp. He has served on the Board of Directors of over 20 public and private healthcare technology companies, and has been the founding investor in numerous medical device start-ups, including Mitralign, Circulite, Accelerated Technologies, Percutaneous Valve Technologies, Applied Spine, and Claros Diagnostics.

• Jake Giannotti, Senior Director, Corporate M&A and BD, Philips Health Systems

Jake joined Philips in 2010, and now serves as Senior Director, Corporate M&A and Business Development, leading all M&A activity for the various healthcare businesses within Philips. In this role, Jake supports Philips’ broad portfolio, including informatics, monitoring, imaging, and respiratory care, to develop inorganic growth strategy, and create and manage supporting acquisitions, partnerships and key strategic alliances. Prior to joining Philips, Jake was a Vice President at Leerink Partners, a leading boutique, healthcare-focused investment bank and advisory �rm, where he focused on both M&A and �nancing for emerging-growth companies in the device, biopharmaceutical, diagnostic and IT markets. Jake holds a B.S. in Finance and Marketing from Boston College.

34

track 2 panelists1:00 - 1:50 pm

DIAGNOSTIC INVESTORSTrack 2

• Parker Cassidy, Executive in Residence, RA Capital Management

Parker Cassidy is currently an Executive in Residence with RA Capital Management, a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices and diagnostics. Parker leverages his operating experience to lead diligence and serve as a catalyst for new company funding and formation. He also serves on the board of Quad Technologies, Inc. Parker has spent his career developing and commercializing new life science products. He most recently served as Vice President, Continuous Glucose Monitoring for BD, leading an internal startup developing a breakthrough product for continuous glucose monitoring. Prior to this role, he held general management, strategy, product, and business development roles for BD’s molecular diagnostics business where he led a $275M acquisition and integration, development and launch of two FDA cleared instrument systems and multiple assays. Before joining BD, he was VP/GM for Serologicals where he led a $70M acquisition and subsequent integration, and helped grow annual sales from <$20M to nearly $60M over six years. Parker earned a BS in Mechanical Engineering from Boston University and an MBA from the University of Virginia (Darden).

M

• Bob Williams, VP of Business Development & Innovation, Bracco Diagnostics

Bob continues to serve in a technical marketing – business development capacity for medical device and imaging companies for over 10 years. Currently manages Medical Device and HIT business development activities for Bracco SpA, Milan, Italy. Experience includes acquisitions, divestitures, exits, joint ventures and partnering for a variety of entities operating in diagnostic imaging, interventional radiology and cardiology. Has ushered numerous deals and early stage business opportunities through various organizations to commercialization. Specialties include product strategy, IP strategy, market analysis and business planning. Bob is also an active member of the Life Science Angel Network (LSAN), New York since its inception. In an angel capacity, Bob performs opportunity screening, market/valuation analysis to angel network members and offers mentorship / advisory support to entrepreneurs seeking seed for healthcare and medical device business opportunities. An engineer by education, prior to his BD roles, Bob has participated in and led numerous medical device development and marketing programs activities for infusion, injection, patient monitoring and consumable products.

• Charles Moehle, VP of Business Development & Licensing, Illumina

Charles Moehle is VP of Business Development and Licensing at Illumina, Inc. He and his team support Illumina’s business and functional units in sourcing and negotiating licenses, supply agreements and various types of partnerships with academic researchers and other companies. Illumina is always looking to license, jointly-develop or acquire improved, new, and disruptive technologies related to its genomic analysis business. Prior to joining Illumina, Charlie was VP of Business Development and Licensing at Applied Biosystems/Life Technologies for eight years where he was responsible for a $100+ MM/year licensing and OEM program, including settlement of several signi�cant patent disputes with competitor companies. Prior to moving into the research tools industry, he worked in Business Development at Chiron Corporation and at Genelabs Technologies. Before that he was Director of Research at Ribogene, Inc and worked for �ve years at the National Institutes of Health after earning his Ph.D. In Yeast Genetics from Carnegie Mellon University.

• John Steuart, Venture Partner, Prolog Ventures

John has been managing venture capital funds for more than 15 years, at Ala� Capital, Claremont Creek Ventures and Prolog Ventures. John also co-founded CyberGold, an Internet payments and loyalty marketing company. The founding team built the company from three co-founders to 150 employees and took it public. After that came a $500 million merger with a competitor, Mypoints. The combined company was acquired by United Airlines. John spent the next couple of years working at its corporate VC arm, United Airlines New Ventures. In 2007, John led the Series A investment in Natera together with Sequoia Capital. The molecular diagnostic company successfully completed an IPO in July 2015. John currently invests in testing technologies and digital health. In August Roche acquired John's portfolio company GeneWeave for $425 million. John currently serves on the boards of Natera (NTRA), SmartZip, TOMA Bio, and Rally4.

• Joe Cunningham, Managing Director, Santé Ventures

Joe Cunningham is a Founding Partner and Managing Director of Santé Ventures, an early-stage life science and healthcare venture capital company based in Austin, Texas. Prior to this Joe was a healthcare Venture Partner with Austin Ventures and was previously the Vice Chair of the Ascension Health Ventures investment committee. He is also the former Chief Medical Of�cer of the Providence Health System and Executive Director of the 300-physician Providence Health Alliance, both of which belong to the Ascension Health system. He has extensive management experience and is recognized nationally for his expertise in healthcare delivery systems, physician associations and compensation models. Joe serves on Advisory Boards for both United Healthcare and for Health Services Corporation (BC/BS). He is board certi�ed in both Internal Medicine and Quality Assurance and Peer Review. Dr. Cunningham received his BS and MD degrees from Texas A&M University and his MBA from Baylor University.

35

tales from the roadtrack 2 panelists2:00 - 2:50 Pm

• Richard Berenson, CEO, Thermalin Diabetes

Rick has been leading organizations and developing practical, break-through strategy for more than twenty years. He has been CEO or COO at 9 startups –brought in by the investors on an interim basis to effect a new strategic direction. Rick has worked across a broad range of industries and can master new technologies and markets with speed –letting him get right to work addressing the fundamental business issues which otherwise keep you from succeeding. Rick began his career at AT&T Bell Laboratories as a member of technical staff where he helped launch internal ventures. He then spent several years at software startups in the Boston area before joining McKinsey & Company as a management consultant. Subsequently, Rick has been CEO of ActivBiotics (early stage biotech), Banton Precision Wood Products (consumer products manufacturer), NewSphere (knowledge management software), Student.Com, Inc. (new media), and TVGrid (technology for the entertainment industry). He has also served as COO at ChannelHealth.Com (healthcare information and services), Morpace Pharma Group (medical market research), and AltiComm (telecom). Rick has been president of Alliance Management Consultants-US and, most recently, a senior partner at Monadnock Associates. Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.

M

• Davis Brimer, CEO, Founder, Director, ActiveLife Scienti�c

Davis is a recognized thought-leader and award-winning entrepreneur. Davis leads ActiveLife’s vision and strategy alongside a dedicated, mission-aligned and highly skilled team to develop and establish new thought, science, and technology within global scienti�c and medical communities. Since the Company’s inception, Davis has balanced the needs of all stakeholders - including employees, investors, customers, and patients - without losing site of ActiveLife’s vision of enabling active living. Davis is a frequent speaker on topics of entrepreneurship, healthcare, and the future of technology. Prior to founding ActiveLife, he was co-host of an entrepreneurship and innovation focused FM talk show and program aired on cable television. Davis received a BS in Computer Engineering and Certi�cate in Entrepreneurship from the UC Santa Barbara College of Engineering.

• Paul Molloy, President & CEO, ClearFlow

Paul is CEO at California based ClearFlow Inc. and has over twenty years experience of management and Board experience at public and VC funded med-tech companies. He has participated in two IPO’s at previous companies, notably as President & Managing Director at LMA’s successful 2005 SGX (Singapore) public listing. Tele�ex later acquired this Company in a process that he brokered. Paul was a practicing CRNA until entering the medical device industry in 1989, obtaining his MBA from the University of Chicago’s Booth School of Business and rising through executive positions with leading medical device �rms to CEO level in successive start ups, most recently completing the sale of VasoNova to Tele�ex Inc. He has extensive global industry connections and has traveled, lived and worked in Asia, Europe and the USA, including substantial experience setting up and managing operations in those areas and serving on the board of several international subsidiaries. He serves on the board and audit committee of CAS Medical, a NASDAQ listed medical device company and is a Board member of Silicon Valley start-up Velano Vascular.

• Shantanu Gaur, Co-Founder & CSO, Allurion Technologies

Dr. Shantanu Gaur co-founded Allurion in 2009 during his second year at Harvard Medical School and is our Chief Scienti�c Of�cer. A Paul & Daisy Soros Fellow, Shantanu graduated summa cum laude and Phi Beta Kappa from Harvard College with an S.B. in Biology and signi�cant coursework in polymer chemistry. Shantanu graduated from Harvard Medical School in 2013. He grew up in Pittsburgh, Pennsylvania and lives in Cambridge, Massachusetts.

• Zoë Barry, Founder & CEO, ZappRx

Zoë Barry is the Founder and CEO of ZappRx, a digital health company that is modernizing and simplifying the way specialty medications are managed. ZappRx provides a secure collaborative online platform that allows patients, physicians and pharmacists to work together to improve patients’ access to treatment, delivering medicine faster, with fewer hassles and greater transparency. Recently named to Inc. Magazine's 30 under 30, Zoë began her career originating and executing high-return strategic investments at a hedge fund in New York. In 2011, Zoë joined AthenaHealth as her �rst foray into the industry, but quickly realized the inef�ciencies in e-prescribing and left AthenaHealth to launch ZappRx in 2012. ZappRx counts Atlas Venture and SR One, the venture arm of GlaxoSmithKline, as institutional investors and has raised over $10M of capital to date. A fellow in Boston’s Startup Leadership Program and graduate of Columbia University, she currently mentors budding entrepreneurs in the Columbia College Women in Business Society.

Track 2

36

global INVESTORStrack 2 panelists3:00 - 3:50 pm

M• Lisa Rhoads, Managing Director, Easton Capital

Lisa joined Easton Capital in 2010 when she repatriated from Bermuda. Lisa was previously with Celtic Pharma, a Bermuda-based global biotech private equity �rm where she was a founding member of the management team. Lisa's spent the last 7 years acquiring and developing a portfolio of later-stage biotech programs where she was involved with all aspects of the development process and managed Intellectual Property portfolio. Lisa has been involved in all aspects of the investment and development process and sits on the board of electroCore, PerceptiMed, Shimojani, and observer board role for Resolve. Lisa also sits on the board at America’s Best Home Healthcare, a home healthcare company. Prior to her role with Celtic Pharma, Lisa consulted and helped launched a number of Hedge Funds and has held senior positions in the Pharma industry with Bristol Myers Squibb J&J's McNeil Consumer Products Company and Zeneca's US pharmaceutical division.

• Christopher Kim, Managing Partner, Korea-Seoul Life Science Fund

Dr. Kim is Managing Partner of the Korea-Seoul Life Science Fund (KSLSF). KSLSF is a cross-border venture capital fund that invests in life sciences companies in Korea and the US. Dr. Kim is responsible for all aspects of its investment and operations. KSLSF has of�ces in Seoul and Boston. Dr. Kim co-founded KSLSF as an entrepreneur-in-residence while at Oxford Bioscience Partners, a Boston-based biotech-focused VC �rm, where he is a partner at the �rm. The �rm has invested in numerous biotech companies over the past 20 years. Previously, Dr. Kim was responsible for biomarker portfolio management as Associate Director and Head of Operations for the Global BioMarker Development group at the Novartis Institutes for BioMedical Research. He held additional role in corporate development and strategy while at Novartis. Previously, Dr. Kim was a member of the IBM Extreme Blue program, providing strategic direction for IBM Healthcare and Life Sciences. At Alkermes, he conducted discovery and preclinical research. Throughout his career, Dr. Kim has served as an advisor or consultant to multiple investment �rms and biotech companies. Dr. Kim received an MBA from Carnegie Mellon University, a Ph.D. in Biomedical Sciences from the University of Texas Health Science Center and the MD Anderson Cancer Center with a focus on developmental biology, and a BA in Economics and BS in Biology from the University of California at Irvine.

• Weiyong Sun, Senior Director, External Scienti�c Affairs, Daiichi Sankyo Group

Dr. Weiyong Sun is currently Senior Director, External Scienti�c Affairs at Daiichi Sankyo Pharma Development. He joined Daiichi Sankyo Japan in April 2002. He was involved in a broad range of R&D activities from target discovery to clinical development of a number of anti-diabetes drugs. In October 2007, Dr. Sun was elected to be assigned to work for Daiichi Sankyo Research Institute in the U.S. He was responsible for identifying and evaluating in-licensing, partnering and research collaboration opportunities. His current focus is in Cardiovascular, Metabolism and Frontier therapeutic areas. Dr. Sun received an M.D. from Beijing Medical University (now Peking University Medical School), a Ph.D. in Biochemistry from the University of Tokyo and an MBA from Columbia Business School. He was a postdoctoral fellow in the Blood Research Institute, Medical College of Wisconsin.

• Winston Town, Vice President, Diamond BioFund

Winston joined Microbio Group in March 2013 and currently serves as Vice President at Diamond BioFund Inc., a specialized health care venture capital �rm with US$300 million under management and Chairman and President of Fountain Biopharma Inc. Winston was formerly Chief Executive Of�cer of Panacor Bioscience and spearheaded a successful new drug development in the nephrology �eld in collaboration with pharmaceutical companies in the United States and Japan. Prior to that, Winston served as Senior Vice President with GloboAsia, a drug development consultation company. He has consulted and worked on numerous drug development projects involving multiple collaborative parties worldwide covering Africa, Asia as well as N. America. Winston has in-depth work experience with pharmaceutical companies in Asia and the United States in designing and implementing development and commercialization strategies. He is also well connected in the �nancial communities around the world.

• Luis Barros, Managing Partner, Leading Business Ventures & Venture Partner, Portugal Capital Ventures

Luis M. Barros, nominated to President Obama’s Homeland Security Science and Technology Advisory Committee (HSSTAC), founded Leading Business Ventures (“LBV”) in 2010, and serves as Venture Partner of Portugal Ventures’ $800M venture capital �rm and its Acceleration Center; and Advisor to Innovation entities in Latin America and Africa. Past af�liations include appointment as Co-Director of Innovation at MIT’s School of Engineering’s Portugal Program (MPP), and Advisor to H3 Biomedicine (Eisai Co. Ltd) & the SBIR Commercialization Assistance Programs (CAP). Prior to LBV, Luis served as the Senior VP of Investments at Massachusetts Life Sciences Center (MLSC) and Principal at Lilly Ventures, on the team that architected these initiatives that yielded the following portfolio: Pluromed (acq'd by Sano�), Boston Biochem (acq'd by Techne Corp), InVivo Therapeutics (OTC: NVIV.OB), Good Start Genetics, 4s3 Bioscience & Avaxia (Series A exits); Phase Forward (NASDAQ: PFWD; acq'd by Oracle), Relay Health (acq'd by McKesson), Fast Track Systems (acq'd by Medidata); MedManage (acq'd by Physicians Interactive), NexCura (acq'd by Thomson Scienti�c); and Innocentive. Prior positions include IC Sciences Corp, Securities and Exchange Commission (SEC) and executive roles in startups that were respectively acquired by TIBCO (NASDAQ:TIBX) and Microsoft (NYSE: MSFT). Luis has degrees from MIT Sloan (MBA) and UMASS Amherst (BBA), and completed HBS’ Corporate Governance and Board Leadership Program.

Track 2

37

healthcare it investors4:00 - 4:50 Pm track 2 panelists

Track 2

• Barbara Gamez Sims, Technology Licensing Manager, Mayo Clinic Ventures

Barbara Gamez Sims joined Mayo Clinic Ventures in 2005 as a licensing manager. Her primary areas of expertise include diagnostics, therapeutics and biotechnology. Prior to coming to Mayo Clinic, Barbara was an attorney in private practice. She received a B.A. in biology from Wartburg College and a J.D. from Marquette University Law School, where she concentrated on intellectual property and was a member of the Marquette Intellectual Property Law Review.

• Aaron Nelson, General Partner, dRx Capital

Aaron is a General Partner at dRx Capital, and he is also a Strategic Project Leader within the Trials of The Future team of Novartis Pharmaceuticals. In recent years, Aaron has worked on technology strategy for clinical trial teams within Novartis. This work has lead him to conclude that mobile, cloud and Health IT technologies provide transformative opportunities in the clinical research and pharmaceutical industries. Aaron has lead projects building upon these themes across multiple Business Units within Novartis, often by collaborations or investments in early-stage partner companies. Previously, Aaron lead laboratory teams at Novartis, investigating the biological bases for drug toxicity. Aaron studied medicine at Tufts University, cell and microbiology at the University of Pennsylvania and the Karolinska Institute, and completed his undergraduate studies at Cornell University.

• Gabe Ling, Venture Partner, General Catalyst

Gabe originally joined General Catalyst over a decade ago to identify and invest in great technology companies. Since then, he has helped hatch new companies, taken operating and corporate development roles directly in portfolio companies, and worked with some fantastic founders. Most recently, he has been collaborating with XIRs and entrepreneurs to build transformational companies by leveraging General Catalyst’s unique ecosystem and entrepreneurial culture. Companies he has led investments in or been involved with include BBN Technologies (acquired by Raytheon Company), CLEAResult (acquired by General Atlantic), Datalogix (acquired by Oracle), Datto, Oceans Healthcare, OGSystems, and Reveal Imaging (acquired by SAIC). Today, Gabe spends most of his time looking for great entrepreneurs where General Catalyst can be uniquely helpful in building their companies. He is particularly interested in digital health businesses that leverage technology and data-analytics to address the convergence of big data, value-based care, and the “consumerization” of healthcare. His other areas of interest include enterprise software, vertical SaaS, and innovative data-driven businesses. Before joining General Catalyst, Gabe earned a B.A. in Economics from Yale University and worked at the Yale Investments Of�ce, which manages the university’s endowment and is recognized as a pioneering institutional investor.

• Hyuk-Jeen Suh, Head of East Coast Of�ce, Samsung Ventures

Hyuk-Jeen Suh joined Samsung Ventures in 2012 and is the head of the Samsung Ventures East Coast of�ce. Before joining Samsung Ventures, Hyuk-Jeen worked at J.P. Morgan investment banking in the Technology, Media, and Telecom group. Prior to J.P. Morgan, he was the global senior business development and marketing manager at MEMSIC, a semiconductor startup with clients in the automobile and consumer electronics industry. He led the global marketing strategy which contributed to the successful IPO of MEMSIC in 2007. Prior to joining MEMSIC, Hyuk-Jeen was a senior research engineer at Sequenom, a biotech startup. He conducted research on DNA biochips and led joint venture projects with Hitachi and Samsung to design high-throughput bio instruments. He began his career at Intel Corporation as a process engineer, leading yield improvement projects which contributed to one of the highest yield rates in Intel history for the Pentium microprocessor. He advises various startup companies and is a mentor at startup accelerators such as TechStars. He has been a guest speaker at Harvard University, Yale University, and MIT and judges for the MIT $100K entrepreneurship competition. Hyuk-Jeen earned his Ph.D. in electrical engineering, focusing on Microelectromechanical Systems (MEMS) from University of Illinois at Urbana-Champaign. He earned his MBA from Yale School of Management. He holds a B.S. in mechanical engineering, B.A in economics and M.E in electrical engineering, all from Cornell University.

• Michael Jin, Managing Partner, TEEC Angel Fund

Dr. Michael (Xuecheng) Jin is the founding partner of TEEC Angel Fund, a super angel fund in Silicon Valley since July 2010 with close to 100 startups under portfolio, and also on the Board/Advisory Board of six BioMed companies. Dr. Jin has extensive investment experiences in biomedical and health tech areas, and was co-founder of four high-tech startups in Silicon Valley and China, with the latest exit of iWatt to Dialog Semiconductor in July 2013 at $345M. He is Board Director of Tsinghua Entrepreneur & Executive Club (TEEC), and Co-Chair of TEEC Life Science and Health Tech Committee. Dr. Jin received BEng & MEng degrees from Tsinghua University in Biomedical Engineering, and PhD degree from Stanford University as the pioneering inventor of capacitive micromachined transducer for medical ultrasound, with more than 40 publications in international journals and conferences, 4 best paper co-author awards, and over a dozen United States patents.

M

Workshops

8:00 AM-

8:50 AM

9:00 AM-

9:50 AM

11:00 AM-

11:50 AM

1:00 PM-

1:50 PM

2:00 PM-

2:50 PM

3:00 PM-

3:50 PM

4:00 PM-

4:50 PM

• Danielle Silva, VP of Business Development

• Ram May-Ron, Managing Partner

• Ed Jameson, CPA, Managing Member

• Aitana Peire, Business Analyst

• Byron Kalogerou, Partner, Boston

• Eric Orsic, Partner, Chicago

• Joanna Lin, Associate, Dallas

• Michael Quigley, Director of Research

• Colin Widen, CEO

• Dennis Ford, Founder & CEO

boston innovation capital

Non-DilutiveFunding

Government Grants& Contracts

Reg A+A New Capital Raising

Alternative

How to ValueYour Startup

branding &messaging

Fundraisingboot camp

RESEARCHINGGLOBAL INVESTORS

Boston Innovation Capital

38

early stage ENTREPRENEUR workshopstrack 3

Sponsored by:


LIFE SCIENCENATION


LIFE SCIENCENATION


LIFE SCIENCENATION

39

early stage ENTREPRENEUR workshops

• Ram May-Ron, Managing Partner, FreeMind GroupWorkshop: Non-Dilutive Funding as a Strategic Source of Funding

For over a decade Ram May-Ron has been a leading �gure within FreeMind. Initially leading FreeMind’s Professional Services Department and later becoming a partner and taking upon himself the full responsibilities of both FreeMind’s marketing and business development efforts, as well as the overall management of FreeMind’s professional services activities. Mr. May-Ron has more than 15 years of experience as a leading strategic analyst, both in the business and political sectors. He has led a strategic consulting �rm and has served as a top strategy adviser to several international organizations and elected political of�cials. Mr. May-Ron serves on the board of directors for several companies and has a wide range of experience in marketing and business development. Mr. May-Ron holds an MEI (Master of Entrepreneurship and Innovation, International Business Management) from Australia’s Swinburne University of Technology. He also holds a Masters degree in International Relations, focusing on strategic decision making processes from the Hebrew University of Jerusalem, winning the International Relations Department’s academic excellence scholarship.

• Ed Jameson, CPA, Managing Member, Jameson & CompanyWorkshop: Understanding the Strings Attached to Government Funding Awards

As a second-generation CEO of Jameson & Company, LLC, you could say that government grants, contracts, audits, and protecting clients are in Ed's blood. After serving as a senior consultant in the small business and tax departments at Price Waterhouse, Boston, Ed joined the �rm in 1988. Since then, he's helped clients secure, account for, and survive audit on more than $3 billion in government grants and contracts. Ed's highly experienced in the indirect rate recovery process and has settled thousands of incurred cost audits. He consults on cost recovery, strategic and tactical management issues, and contract and grant cost procurement; in addition, he oversees all client relationships. Ed enjoys educating (and entertaining) an audience and has been a featured speaker at the National SBIR conference for years. His personal life mirrors his business life—it's all about protecting and helping others. A longtime member of Rotary International and past president of the Burlington Rotary Club, Ed was honored with the Paul Harris Fellow Award for service above self. He leads a group of volunteers each month to prepare dinner and serve approximately 300 men at the Pine Street Inn, a Boston homeless shelter.

• Byron Kalogerou, Partner, McDermott Will & Emery, BostonWorkshop: Reg A+ - A New Capital Raising Alternative for Life Science Companies

Byron S. Kalogerou is the Chair of the Firm’s Life Science Industry Group and head of the Boston Corporate Advisory Practice Group. Byron focuses his practice on domestic and cross border mergers and acquisitions, corporate �nance and joint ventures and alliances. He has substantial on the ground experience in structuring mergers, acquisitions, divestitures and joint ventures on six continents. Byron has extensive industry background in the medical device, �re and security, energy, telecom and industrial sectors. Before his move back to private practice, Byron spent 17 years in-house, including 14 years at Tyco International, where he served in a variety of roles including as general counsel of its �re and security business, its telecommunications business and as general counsel of its international legal department, a function he created. He has handled hundreds of M&A transactions. These include Tyco's most signi�cant transactions, including the $12 billion acquisition of AMP Inc., the $850 million purchase of AT&T Submarine Systems, and the $2.2 billion initial public offering of TyCom Ltd. In addition, he handled many of Tyco’s medical device company acquisitions.

• Eric Orsic, Partner, McDermott Will & Emery, ChicagoWorkshop: Reg A+ - A New Capital Raising Alternative for Life Science Companies

Eric Orsic is a partner in the law �rm of McDermott Will & Emery LLP and is based in the Firm’s Chicago of�ce. Eric focuses his practice in the areas of mergers and acquisitions, and securities transactions and compliance. Eric works with both public and privately-held companies to structure and negotiate business acquisitions/dispositions. His public company transactional experience includes public equity and debt offerings, tender offers and going-private transactions. Eric also serves as outside securities counsel to several public companies and advises on SEC compliance matters, including periodic reporting requirements and disclosure issues. In addition, Eric works with both public and private companies in the design and structuring of executive compensation programs, including stock and stock-based compensation plans. Eric is a frequent writer and speaker on corporate and securities law matters. His publications include “Federal Securities Laws Considerations for Equity Compensation Plans,” Selected Issues in Equity Compensation, 11th ed., published by the National Center for Employee Ownership.

presenters

• Danielle Silva, VP of Business Development, Life Science NationWorkshop: Fundraising Boot Camp

Danielle is a founding partner of Life Science Nation and helps companies developing therapeutics, medical devices develop their outbound marketing campaign and identify fundraising partners. Previously, Danielle was a marketer for a multi-family of�ce with over $4 billion in assets under management. Danielle �rst started her career as a research analyst at Brighton House Associates, assisting fund managers in the hedge fund, private equity, and venture capital space raise money via institutional alternative investors. Danielle has been quoted in a variety of publications in the alternative investment space including the Wall Street Journal, the Financial Times, and Jim Cramer’s “The Street”. Danielle received her Bachelor’s degree in Economics and Policy Studies from the Maxwell School at Syracuse University.

40

early stage ENTREPRENEUR workshops

• Colin Widen, CEO, Boston Innovation CapitalWorkshop: Boston Innovation Capital

Colin Widen is a seasoned executive with 25 years of sales, trading and portfolio management experience in major investment banks. In 2001, Colin left the institutional world and founded W.A.M. Asset Management, a private equity fund of funds that focused on SBIC private equity funds. After selling the �rm to a larger fund of funds, Colin joined Deutsche Bank where he led a team providing consulting services about alternative asset allocation strategies to family of�ces and smaller endowments and foundations. Colin is a registered representative with StillPoint Capital and holds Series 7, 24, 63 and 82 registrations. His specialties include reconstructing hedge fund portfolios and analyzing private equity holdings.

• Michael Quigley, Director of Research, Life Science NationWorkshop: Researching Global Investors

Michael Quigley is the Director of Research for LSN in Boston, Massachusetts. He has been with the company for 2 years, researching life science investors from around the globe. In addition to managing a team of research analysts in the US and abroad, Michael is the Co-Editor of LSN’s Next Phase Newsletter, where he and his team write about their latest discoveries from the life science private investment ecosystem. Michael’s passion for the life science industry was sparked by a course he took while earning his bachelor’s degree in Economics and Finance at Bentley University. During the course, entitled The Business of Biotech, Michael quickly became aware of the massive �nancing needs required to get a medical product approved and into the hands of doctors and patients. This massive need for capital paired with the lack of forward-looking data available on private investors is what drew him to work in investor research for LSN.

• Aitana Peire, Business Analyst, Venture ValuationWorkshop: How to Value Your Startup

Before joining Venture Valuation in 2013 as business analyst, Aitana worked as Pharma equity research analyst for Kepler Cheuvreux, covering small caps. Prior to that, she worked as consultant for Stratas Partners, based in Basel, focusing on projects on market access, pricing and reimbursement, and budget impact modelling. Aitana holds a PhD in Evolutionary Genetics from the University of Groningen (Netherlands) and is a CFA Level II candidate.

• Joanna Lin, Associate, McDermott Will & Emery, DallasWorkshop: Reg A+ - A New Capital Raising Alternative for Life Science Companies

Joanna Lin is an associate in the law �rm of McDermott Will & Emery LLP and is based in the Firm’s Boston of�ce. She focuses her practice on corporate and securities law, including venture �nancing transactions, and mergers and acquisitions for public and private companies. Joanna has extensive experience in cross-border mergers and acquisitions. She also has experience with capital markets transactions, having represented U.S. and international issuers, investment banks and investors in a wide range of securities offerings, including IPOs, follow-on offerings and private placements of equity securities. She also regularly counsels clients on matters ranging from corporate governance to SEC periodic reporting requirements and other general corporate matters. Joanna’s clients have represented a broad array of industries, including both technology and life science sectors. Joanna is pro bono attorney for Kids in Need of Defense in Boston, representing children in need of immigration-related legal representation. She is also a regional board member of the Boston chapter of Many Hopes, a non-pro�t organization that houses and educates orphaned and abandoned children in Kenya.

• Dennis Ford, Founder & CEO, Life Science NationWorkshop: Branding & Messaging

Dennis Ford is an entrepreneur and author with expertise in sales, marketing, and business development. He has spent most of his career launching new companies. Over the last decade, he has worked extensively with global alternative investors interested in high-growth early-stage technologies. His expertise encompasses using database subscription services to create business solutions and using the Internet to create an interactive dialog between buyers and sellers. He is a big proponent of using pro�ling and matching technology to �nd that all-important business �t in the marketing and selling process. Before LSN, Dennis was the President and CEO of Brighton House Associates (BHA). BHA was launched in order to improve the way hedge fund and private equity fund managers raised capital and marketed their funds to investors. Ford is the author of The Peddler’s Prerogative and The Fund Manager’s Marketing Manifesto, two well-received sales and marketing books. His latest book is The Life Science Executive’s Fundraising Manifesto. Ford teaches Entrepreneurship Sales & Marketing to undergraduate and graduate students at the University of Massachusetts Boston.

presenters

RESI provides a partnering forum for all stakeholders in the early stage life science world to reach out to others and build the relationships that will carry new technologies towards commercialization.

41

partnering forum

Active early stageInvestors

Who Met with Whom at RESI@TMCx

RESI Boston 2015 Investor Breakdown

ACROSS 10 CATEGORIES

dYNAMICpARTNERING FOrUM

based on fit

As of June 8, 2015

track 4

Sponsored by:

1%

2%

4%

5%

14%

75%

Service Provider & Service Provider

Startup & Startup

Investor & Service Provider

Investor & Investor

Startup & Service Provider

Startup & Investor

4% 7%

9%

11%

13%

17%

19%

20%

Government Organization

Endowments/Foundations

PE

Family Office/Private Wealth

Angel

Corporate Venture Capital

Large Pharma/Biotech

Venture Capital

Bronze Sponsors

42

SPONSORS

Gold Sponsors

Title Sponsors

Silver Sponsors

JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and of�ce space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas.

McDermott Will & Emery is a premier international law �rm with a diversi�ed business practice. Established in 1934 as a tax practice in Chicago, Illinois, we have of�ces in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. McDermott has 80 years of serving a broad range of client interests. Our Life Sciences Industry Group is composed of 135 professionals, 60 with advanced science degrees and many others with government and industry experience, working across 19 of�ces around the world. With insights drawn from the only health practice ranked Tier 1 nationally by Chambers USA and our global reach, we deliver integrated business solutions to our clients, bringing the required experience from our leading tax, health, intellectual property, antitrust and regulatory practices to solve our client’s challenges.

The drug research and development process is highly complex, lengthy and expensive, yet essential for delivering safe and effective therapies to patients. Even though the process is reasonably well-de�ned, drug development programs are fundamentally different for each product, as the exact testing and submission requirements are shaped by many unique factors. To help our customers navigate this process, Charles River offers a wide range of products and services that span the entire drug discovery and development continuum and can be tailored to speci�c research conditions.

Life Science Nation (LSN) accelerates fundraising using its matching platform to create highly compatible relationships between early stage scientists/ entrepreneurs and emerging technology investors. LSN researches and curates market intelligence on two industry sectors. The �rst is emerging biotech and medtech companies, which by their ephemeral nature are challenging to �nd and track. Second, LSN tracks ten categories of early stage life science investors and identi�es who is �lling the void left by venture capital. LSN owns and operates the Rede�ning Early Stage Investments (RESI) conference series, which brings together global early stage biotech and medtech companies with early stage investors.

WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the US. As a research-driven and customer-focused company, WuXi provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec’s services are designed to help its global partners in shortening the cycle and lowering the cost of R&D. WuXi is also building a platform to provide clinical diagnostic and genomic services directly to physicians and their patients globally.

AdvaMed 2015 is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international �avor and featuring a deep, diverse attendee list that includes in�uential policy-makers, business executives and media, AdvaMed 2015 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more. It is a “must-attend” event for any MedTech company.

GBBC provides services analyzing business operations of potential and existing investments made by investors in life science companies. The range of services start at the due diligence process of a potential investment opportunity through the management of investments leading to a successful exit strategy. GBBC provides insight into key functions of a medical device and biopharmaceutical startup and early growth stage businesses. The insight will assess a valuation for a business and optimize business operations to meet investor and company �nancial goals.

Atheln is a life science consulting �rm with over 60 industry seasoned experts. We provide project-speci�c virtual teams for hire. Each team includes all the disciplines required for the development of the particular product, including: non-clinical, CMC, quality, project management, regulatory, clinical, new product planning, business development and licensing, market access and reimbursement and others. The team creates strategies for risk control, designs integrated product development plans and manages plan execution for our clients. Our client solutions focus on approvability, manufacturability, reimbursability, fundability, and parterability of their technologies.

Morley Research Consortium (MRC) is a full service Contract Research Organization working primarily with early to mid-stage medical device and biotech/pharma companies on Phase I to Post-Market clinical trials. MRC offers companies currently seeking investment opportunities from funding sources no-cost preliminary evaluations on budgets and timelines needed for commercialization. MRC works with our extensive network of domestic and international clinical sites in over twenty four disciplines to ensure compliant, cost-effective, and timely studies. Positioned as a leader in clinical trials for early and mid-stage companies, MRC conducts clinical trials that satisfy all FDA requirements. When looking for a partner in all regulatory and clinical trial work, look no further than MRC.

At Bristol-Myers Squibb we are developing and bringing medicines to patients that are fundamentally transforming the way cancer is treated. Around the world, our medicines also help millions of people in their �ght against cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS and, rheumatoid arthritis. At Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on diseases with the highest unmet need where we believe we can make a difference. To do this we need great partners. Learn more about collaborating with us: www.bms.com/partnering

43

SPONSORS

Media Partners

44

media partners

45

General information

Network: Westin_Meeting RoomPassword: resi15

wifi

Public Transportation - From Logan Airport

travel

The Westin Copley Place10 Huntington Ave, Boston, MA 02116(617) 262-9600

The Fairmont Copley Plaza138 St James Ave, Boston, MA 02116(617) 267-5300

Boston Marriott Copley Place110 Huntington Ave, Boston, MA 02116(617) 236-5800

Copley Square Hotel47 Huntington Ave, Boston, MA 02116(617) 536-9000

The Colonnade Boston Hotel120 Huntington Ave, Boston, MA 02116(617) 424-7000

The Lenox Hotel61 Exeter St, Boston, MA 02116(617) 536-5300

Boston Park Plaza Hotel50 Park Plaza, Boston, MA 02116(617) 426-2000

W Boston Hotel100 Stuart St, Boston, MA 02116(617) 261-8700

Sheraton Boston Hotel39 Dalton St, Boston, MA 02199(617) 236-2000

Recommended Hotels

General Public Transportation - SubwayThe closest subway stations are Copley Station (on the Green Line) and Back Bay (on the Orange Line). Both stations are within 1 block of the hotel. The MBTA begins service daily from 6:00 AM - 1:00 AM. The cost is $2.65 per ride.

Driving Directions - From Logan Airport

- Take the Ted Williams Tunnel to I-93 North.

- Proceed on I-93 North to Storrow Drive (Exit 26).

- Proceed to Copley Square.

- Turn right onto Beacon, continue for 2 blocks.

- Turn left on Clarendon Street.

- Continue on Clarendon for 5 blocks & turn right on St. James.

- Proceed to the venue.

Option 1: Back Bay Logan Express: From Airport Terminal A, B, C, E (Arrivals Level pick-up at Logan Express stops) to Copley Square. Note: The fare is $5 per passenger; Visa, Mastercard, American Express and Diners Club are accepted: no cash

Option 2: From airport terminal take a Massport shuttle bus to the Airport subway station. Take an inbound Blue Line train to State Street Change at State Street for the Orange Line. Take any Orange Line train to Back Bay station. Exit Back Bay station to Boylston Street. Make a right onto Dartmouth Street; the venue will be on the left.

Option 3: From airport terminal take any Silver Line bus to South Station. Change at South Station for the Red Line. Take an Alewife bound Red line train to Park Street. Change at Park Street for the Green Line. Take any Green Line train to Copley Station. Exit Copley station to Boylston Street. Make a right onto Dartmouth Street. Turn right onto MA-9 W; the venue will be on the right.

Keeping patients at the center of everything we do

MOPQwww.bms.com

by Dennis FordMANIFESTOBEST PRACTICES FOR IDENTIFYING CAPITAL IN THE BIOTECH AND MEDTECH ARENAS

FUNDRAISING

Contributors

The Life Science Executive’s

Robert Cohen, Tom Crosby, Jack Fuller, Nono Hu, Maximilian Klietmann,Gerard O’Connor, Lucy Parkinson, Danielle Silva, and Alejandro Zamorano

R&D Phase III On MarketPreclinical Phase IIPhase I

Family Friends

Angels

Venture Capital Funds (limited)

Family Offices Foundations Venture Philanthropy Patient Groups

Private Equity and Hedge Funds

Large Pharma and Biotech Companies Corporate Venture

!"#$%&'"()&*%)"$*'+,$)*'+&"-'.(-,/0"',$1$%-.2$&"'*"()"$3+$*'

4-('$)(%5'*")3$'6+-.#)(2)'0-2.)&+$*

!"#$%&'(&)'*(&(%"*"&+',-'$&+"%.(+")'*/0+$)$#1$20$&(.3'20(&#

4&&,5(+$5"'5$.+/(0'2.,)/1+')"5"0,2*"&+'(22.,(16

7"(*',-'$&)/#+.3'#"(#,&")'"82".+#'"81"0'$&')"0$5".$&%''#,0/+$,&#'-,.'.$#9'1,&+.,0

4&+"%.(+$,&',-'+"16&$1(0'(&)'1,**".1$(0'1,&#$)".(+$,&#'+,'*(8$*$:"'2.,)/1+'2(.+&".(;$0$+3

7778)"#$%&6+-2$,80-22-&+0)9)"#$%&6+-2$,80-2':'),(+)&)9)"#$%&6+-2$,80-2

'''';<=8>==8=?>=''''''''''''''''''''''''''''@>@8A=>8A>@A

!"#$%&'()*+*,'!-'!./0123'4$5)6)*&278)&--9992 :;01;23999<=>29?@

48

notes

49

notes







Documents

Make a Compelling Connection ONSITE GUIDE · 2017. 8. 25. · big pharma BIOTECH family offices MEDTECH angels fundraising boot camp ... focused on Precision Medicine and will be